{
  "drug_name": "iptacopan",
  "generic_name": "iptacopan",
  "mechanism": "Iptacopan binds to Factor B of the alternative complement pathway and regulates the cleavage of C3, generation of downstream effectors, and the amplification of the terminal pathway. In PNH, intravascular hemolysis (IVH) is mediated by the downstream membrane attack complex (MAC), while extravascular hemolysis (EVH) is facilitated by C3b opsonization. Iptacopan acts proximally in the alternative pathway of the complement cascade to control both C3b-mediated EVH and terminal complement-mediated IVH. In IgAN, the deposition of galactose deficient IgA1 (Gd-IgA1) containing immune complexes in the kidney locally activates the alternative complement pathway which is thought to contribute to the pathogenesis of IgAN. By binding to Factor B, iptacopan inhibits the alternative pathway. In C3G, overactivation of the alternative complement pathway leads to C3 cleavage within the glomeruli resulting in C3 deposition and inflammation, which are thought to contribute to the pathogenesis of C3G. By ",
  "target": null,
  "approved_indications": [
    "oral fabhalta (iptacopan), the first and only treatment approved in c3 glomerulopathy",
    "fabhalta (iptacopan) for the reduction of proteinuria in primary iga nephropathy (igan)",
    "adults with paroxysmal nocturnal hemoglobinuria (pnh)"
  ],
  "opportunities": [
    {
      "extraction": {
        "source": {
          "pmid": "41016978",
          "doi": "10.1007/s00277-025-06591-9",
          "url": "https://pubmed.ncbi.nlm.nih.gov/41016978/",
          "title": "Treatment of transplantation-associated thrombotic microangiopathy with iptacopan: two cases report.",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Peer-reviewed journal",
          "is_open_access": false
        },
        "disease": "Transplantation-associated thrombotic microangiopathy (TA-TMA)",
        "disease_normalized": "Transplantation-associated Thrombotic Microangiopathy",
        "is_off_label": true,
        "is_relevant": true,
        "evidence_level": "Case Series",
        "patient_population": {
          "n_patients": 2,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "cyclosporine discontinuation",
            "basiliximab",
            "mycophenolate mofetil"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "40-year-old male with ETP-ALL post-HSCT and 41-year-old female with AML post-HSCT, both developed TA-TMA"
        },
        "treatment": {
          "drug_name": "iptacopan",
          "generic_name": "iptacopan",
          "mechanism": "Iptacopan binds to Factor B of the alternative complement pathway and regulates the cleavage of C3, generation of downstream effectors, and the amplification of the terminal pathway. In PNH, intravascular hemolysis (IVH) is mediated by the downstream membrane attack complex (MAC), while extravascular hemolysis (EVH) is facilitated by C3b opsonization. Iptacopan acts proximally in the alternative pathway of the complement cascade to control both C3b-mediated EVH and terminal complement-mediated IVH. In IgAN, the deposition of galactose deficient IgA1 (Gd-IgA1) containing immune complexes in the kidney locally activates the alternative complement pathway which is thought to contribute to the pathogenesis of IgAN. By binding to Factor B, iptacopan inhibits the alternative pathway. In C3G, overactivation of the alternative complement pathway leads to C3 cleavage within the glomeruli resulting in C3 deposition and inflammation, which are thought to contribute to the pathogenesis of C3G. By ",
          "target": null,
          "route_of_administration": "oral",
          "dose": "200 mg",
          "frequency": null,
          "duration": "Case 1: 24 days, Case 2: ongoing at 15 months",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "2/2 (100%)",
          "responders_n": 2,
          "responders_pct": 100.0,
          "time_to_response": "7 days",
          "duration_of_response": "Case 1: sustained until death from unrelated cause; Case 2: sustained at 15 months",
          "effect_size_description": "Complete resolution of TMA markers including normalized blood pressure, resolved proteinuria, decreased LDH, improved hemoglobin and platelet counts",
          "primary_endpoint": "Clinical and biochemical recovery from TA-TMA",
          "endpoint_result": "Significant clinical and biochemical recovery in both patients",
          "durability_signal": null,
          "efficacy_summary": "Both patients showed significant clinical and biochemical recovery from TA-TMA with normalization of blood pressure, resolution of proteinuria, decreased LDH levels, and improved hematologic parameters. Recovery was observed within 7 days in both cases."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": 0,
          "sae_percentage": 0.0,
          "discontinuations_n": 0,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "No adverse events attributed to iptacopan were reported in either case. One patient died from disseminated mucormycosis unrelated to iptacopan treatment.",
          "safety_profile": "Favorable"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Strong",
        "comparator_baseline": null,
        "follow_up_duration": "Case 1: 45 days post-HSCT; Case 2: 15 months post-HSCT",
        "key_findings": "First reported use of iptacopan in TA-TMA showing rapid and sustained clinical response in both patients. Iptacopan demonstrated efficacy as a factor B inhibitor targeting the alternative complement pathway in TA-TMA.",
        "detailed_efficacy_endpoints": [
          {
            "endpoint_name": "LDH level",
            "endpoint_category": "Exploratory",
            "timepoint": "Post-treatment (Case 1)",
            "measurement_type": "Change from baseline",
            "value": -220.0,
            "unit": "U/L",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 623.0,
            "final_value": 403.0,
            "change_from_baseline": -220.0,
            "change_pct": -35.3,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Lactate dehydrogenase decrease indicating reduced hemolysis",
            "organ_domain": "Hematological",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Hemoglobin level",
            "endpoint_category": "Exploratory",
            "timepoint": "Post-treatment (Case 1)",
            "measurement_type": "Change from baseline",
            "value": 13.0,
            "unit": "g/L",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 42.0,
            "final_value": 55.0,
            "change_from_baseline": 13.0,
            "change_pct": 31.0,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Hemoglobin improvement in Case 1",
            "organ_domain": "Hematological",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Platelet count",
            "endpoint_category": "Exploratory",
            "timepoint": "Post-treatment (Case 1)",
            "measurement_type": "Change from baseline",
            "value": 12.0,
            "unit": "\u00d7 10^9/L",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 8.0,
            "final_value": 20.0,
            "change_from_baseline": 12.0,
            "change_pct": 150.0,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Platelet count improvement in Case 1",
            "organ_domain": "Hematological",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Serum creatinine",
            "endpoint_category": "Exploratory",
            "timepoint": "Post-treatment (Case 1)",
            "measurement_type": "Change from baseline",
            "value": -24.0,
            "unit": "\u00b5mol/L",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 123.0,
            "final_value": 99.0,
            "change_from_baseline": -24.0,
            "change_pct": -19.5,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Renal function improvement in Case 1",
            "organ_domain": "Renal",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Total bilirubin",
            "endpoint_category": "Exploratory",
            "timepoint": "Post-treatment (Case 1)",
            "measurement_type": "Change from baseline",
            "value": -36.6,
            "unit": "\u00b5mol/L",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 62.8,
            "final_value": 26.2,
            "change_from_baseline": -36.6,
            "change_pct": -58.3,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Bilirubin improvement indicating reduced hemolysis in Case 1",
            "organ_domain": "Hematological",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Soluble C5b-9 level",
            "endpoint_category": "Exploratory",
            "timepoint": "Post-treatment (Case 1)",
            "measurement_type": "Change from baseline",
            "value": -45.0,
            "unit": "ng/mL",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 171.0,
            "final_value": 126.0,
            "change_from_baseline": -45.0,
            "change_pct": -26.3,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Complement activation marker improvement in Case 1",
            "organ_domain": "Immunological",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Blood pressure normalization",
            "endpoint_category": "Exploratory",
            "timepoint": "Post-treatment (Case 1)",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "total_n": 1,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Blood pressure normalized from 140-160/90-110 mmHg in Case 1",
            "organ_domain": "Cardiopulmonary",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Proteinuria resolution",
            "endpoint_category": "Exploratory",
            "timepoint": "Post-treatment (Case 1)",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "total_n": 1,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Proteinuria turned negative in Case 1",
            "organ_domain": "Renal",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "LDH level",
            "endpoint_category": "Exploratory",
            "timepoint": "Post-treatment (Case 2)",
            "measurement_type": "Change from baseline",
            "value": -145.0,
            "unit": "U/L",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 438.0,
            "final_value": 293.0,
            "change_from_baseline": -145.0,
            "change_pct": -33.1,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Lactate dehydrogenase decrease in Case 2",
            "organ_domain": "Hematological",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Total bilirubin",
            "endpoint_category": "Exploratory",
            "timepoint": "Post-treatment (Case 2)",
            "measurement_type": "Change from baseline",
            "value": -50.6,
            "unit": "\u00b5mol/L",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 85.2,
            "final_value": 34.6,
            "change_from_baseline": -50.6,
            "change_pct": -59.4,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Bilirubin improvement in Case 2",
            "organ_domain": "Hematological",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Soluble C5b-9 level",
            "endpoint_category": "Exploratory",
            "timepoint": "Post-treatment (Case 2)",
            "measurement_type": "Change from baseline",
            "value": -36.0,
            "unit": "ng/mL",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 190.0,
            "final_value": 154.0,
            "change_from_baseline": -36.0,
            "change_pct": -18.9,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Complement activation marker improvement in Case 2",
            "organ_domain": "Immunological",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Blood pressure normalization",
            "endpoint_category": "Exploratory",
            "timepoint": "Post-treatment (Case 2)",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "total_n": 1,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Blood pressure returned to normal from 140-150/90-100 mmHg in Case 2",
            "organ_domain": "Cardiopulmonary",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Proteinuria resolution",
            "endpoint_category": "Exploratory",
            "timepoint": "Post-treatment (Case 2)",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "total_n": 1,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Proteinuria resolved in Case 2",
            "organ_domain": "Renal",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Diarrhea resolution",
            "endpoint_category": "Exploratory",
            "timepoint": "Post-treatment (Case 2)",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "total_n": 1,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Diarrhea completely resolved in Case 2",
            "organ_domain": "Gastrointestinal",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Clinical and biochemical recovery",
            "endpoint_category": "Exploratory",
            "timepoint": "Post-treatment",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "total_n": 2,
            "responders_n": 2,
            "responders_pct": 100.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Both patients achieved significant clinical and biochemical recovery",
            "organ_domain": "Systemic",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "TMA resolution",
            "endpoint_category": "Exploratory",
            "timepoint": "Post-treatment (Case 1)",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "total_n": 1,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Resolution of thrombotic microangiopathy in Case 1",
            "organ_domain": "Systemic",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          }
        ],
        "detailed_safety_endpoints": [
          {
            "event_name": "Headache",
            "event_category": "AE",
            "severity_grade": null,
            "patients_affected_n": null,
            "patients_affected_pct": 16.0,
            "events_total": null,
            "relatedness": null,
            "outcome": null,
            "action_taken": null,
            "notes": "From APPLY-PNH trial",
            "category_soc": "Neurological",
            "infection_type": null,
            "malignancy_type": null,
            "cv_type": null,
            "thromboembolic_type": null,
            "is_class_effect": false
          },
          {
            "event_name": "Headache",
            "event_category": "AE",
            "severity_grade": null,
            "patients_affected_n": null,
            "patients_affected_pct": 28.0,
            "events_total": null,
            "relatedness": null,
            "outcome": null,
            "action_taken": null,
            "notes": "From APPOINT-PNH trial",
            "category_soc": "Neurological",
            "infection_type": null,
            "malignancy_type": null,
            "cv_type": null,
            "thromboembolic_type": null,
            "is_class_effect": false
          },
          {
            "event_name": "Diarrhea",
            "event_category": "AE",
            "severity_grade": null,
            "patients_affected_n": null,
            "patients_affected_pct": 15.0,
            "events_total": null,
            "relatedness": null,
            "outcome": null,
            "action_taken": null,
            "notes": "From APPLY-PNH trial",
            "category_soc": "Metabolic",
            "infection_type": null,
            "malignancy_type": null,
            "cv_type": null,
            "thromboembolic_type": null,
            "is_class_effect": false
          },
          {
            "event_name": "Diarrhea",
            "event_category": "AE",
            "severity_grade": null,
            "patients_affected_n": null,
            "patients_affected_pct": 8.0,
            "events_total": null,
            "relatedness": null,
            "outcome": null,
            "action_taken": null,
            "notes": "From APPOINT-PNH trial",
            "category_soc": "Metabolic",
            "infection_type": null,
            "malignancy_type": null,
            "cv_type": null,
            "thromboembolic_type": null,
            "is_class_effect": false
          },
          {
            "event_name": "Nasopharyngitis",
            "event_category": "AE",
            "severity_grade": null,
            "patients_affected_n": null,
            "patients_affected_pct": 11.0,
            "events_total": null,
            "relatedness": null,
            "outcome": null,
            "action_taken": null,
            "notes": "From APPLY-PNH trial",
            "category_soc": "Infections",
            "infection_type": "Viral",
            "malignancy_type": null,
            "cv_type": null,
            "thromboembolic_type": null,
            "is_class_effect": false
          },
          {
            "event_name": "Nausea",
            "event_category": "AE",
            "severity_grade": null,
            "patients_affected_n": null,
            "patients_affected_pct": 10.0,
            "events_total": null,
            "relatedness": null,
            "outcome": null,
            "action_taken": null,
            "notes": "From APPLY-PNH trial",
            "category_soc": "Metabolic",
            "infection_type": null,
            "malignancy_type": null,
            "cv_type": null,
            "thromboembolic_type": null,
            "is_class_effect": false
          },
          {
            "event_name": "Nausea",
            "event_category": "AE",
            "severity_grade": null,
            "patients_affected_n": null,
            "patients_affected_pct": 5.0,
            "events_total": null,
            "relatedness": null,
            "outcome": null,
            "action_taken": null,
            "notes": "From APPOINT-PNH trial",
            "category_soc": "Metabolic",
            "infection_type": null,
            "malignancy_type": null,
            "cv_type": null,
            "thromboembolic_type": null,
            "is_class_effect": false
          },
          {
            "event_name": "COVID-19 infection",
            "event_category": "AE",
            "severity_grade": null,
            "patients_affected_n": null,
            "patients_affected_pct": 8.0,
            "events_total": null,
            "relatedness": null,
            "outcome": null,
            "action_taken": null,
            "notes": "From APPLY-PNH trial",
            "category_soc": "Infections",
            "infection_type": "Viral",
            "malignancy_type": null,
            "cv_type": null,
            "thromboembolic_type": null,
            "is_class_effect": false
          },
          {
            "event_name": "COVID-19 infection",
            "event_category": "AE",
            "severity_grade": null,
            "patients_affected_n": null,
            "patients_affected_pct": 15.0,
            "events_total": null,
            "relatedness": null,
            "outcome": null,
            "action_taken": null,
            "notes": "From APPOINT-PNH trial",
            "category_soc": "Infections",
            "infection_type": "Viral",
            "malignancy_type": null,
            "cv_type": null,
            "thromboembolic_type": null,
            "is_class_effect": false
          },
          {
            "event_name": "Upper respiratory tract infection",
            "event_category": "AE",
            "severity_grade": null,
            "patients_affected_n": null,
            "patients_affected_pct": 3.0,
            "events_total": null,
            "relatedness": null,
            "outcome": null,
            "action_taken": null,
            "notes": "From APPLY-PNH trial",
            "category_soc": "Infections",
            "infection_type": "Bacterial",
            "malignancy_type": null,
            "cv_type": null,
            "thromboembolic_type": null,
            "is_class_effect": false
          },
          {
            "event_name": "Upper respiratory tract infection",
            "event_category": "AE",
            "severity_grade": null,
            "patients_affected_n": null,
            "patients_affected_pct": 12.0,
            "events_total": null,
            "relatedness": null,
            "outcome": null,
            "action_taken": null,
            "notes": "From APPOINT-PNH trial",
            "category_soc": "Infections",
            "infection_type": "Bacterial",
            "malignancy_type": null,
            "cv_type": null,
            "thromboembolic_type": null,
            "is_class_effect": false
          },
          {
            "event_name": "Serious adverse events",
            "event_category": "SAE",
            "severity_grade": null,
            "patients_affected_n": null,
            "patients_affected_pct": 10.0,
            "events_total": null,
            "relatedness": null,
            "outcome": null,
            "action_taken": null,
            "notes": "Occurred in 10% of patients in both APPLY-PNH and APPOINT-PNH trials",
            "category_soc": "Metabolic",
            "infection_type": null,
            "malignancy_type": null,
            "cv_type": null,
            "thromboembolic_type": null,
            "is_class_effect": false
          },
          {
            "event_name": "Disseminated mucormycosis",
            "event_category": "AE",
            "severity_grade": null,
            "patients_affected_n": 1,
            "patients_affected_pct": null,
            "events_total": null,
            "relatedness": "Unrelated",
            "outcome": "Fatal",
            "action_taken": null,
            "notes": "Case 1 patient died on day +45 due to disseminated mucormycosis involving paranasal sinuses and lungs despite aggressive isavuconazole therapy",
            "category_soc": "Infections",
            "infection_type": "Fungal",
            "malignancy_type": null,
            "cv_type": null,
            "thromboembolic_type": null,
            "is_class_effect": false
          }
        ],
        "extraction_timestamp": "2025-12-08T00:18:00.278514",
        "extraction_confidence": 0.6,
        "extraction_confidence_detail": null,
        "extraction_method": "multi_stage",
        "extraction_stages_completed": [
          "section_identification",
          "efficacy_extraction",
          "safety_extraction"
        ],
        "data_sections_identified": {
          "baseline_tables": [],
          "efficacy_tables": [],
          "safety_tables": [],
          "efficacy_figures": [
            "Figure 1: Changes in LDH, total bilirubin, hemoglobin, and platelet of case 2"
          ],
          "results_sections": [
            "Case presentations",
            "Case 1",
            "Case 2"
          ],
          "patient_count": 2,
          "study_type": "Case Series",
          "has_quantitative_outcomes": true,
          "notes": "Contains Table 1 comparing iptacopan vs eculizumab characteristics (not patient outcomes). Clinical data presented narratively in case presentations with specific lab values, dates, and treatment responses. Figure 1 shows longitudinal clinical parameters for case 2 only."
        }
      },
      "market_intelligence": {
        "disease": "Transplantation-associated Thrombotic Microangiopathy",
        "epidemiology": {
          "us_prevalence_estimate": null,
          "us_incidence_estimate": "12% of allogeneic transplant recipients",
          "global_prevalence": null,
          "patient_population_size": 2880,
          "prevalence_source": "Transplantation and Cellular Therapy",
          "prevalence_source_url": "https://www.astctjournal.org/article/S2666-6367(22)00029-X/fulltext",
          "trend": null,
          "source_quality": "Primary",
          "data_year": 2022,
          "geographic_scope": "Global",
          "confidence": "Medium",
          "notes": "Pooled incidence from meta-analysis shows 12% of allogeneic transplant recipients develop TA-TMA. US patient estimate based on approximately 24,000 annual allogeneic transplants in US. Incidence varies widely (3-39%) depending on diagnostic criteria used, with provider/clinician diagnosis reporting lowest rates at 3%"
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Eculizumab",
              "drug_class": "Complement C5 inhibitor",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "Used off-label as second-line treatment for TA-TMA based on complement pathway involvement, but not FDA-approved for transplantation-associated TMA specifically"
            },
            {
              "drug_name": "Ravulizumab",
              "drug_class": "Complement C5 inhibitor",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "Long-acting complement inhibitor used off-label for TA-TMA, but not FDA-approved for transplantation-associated TMA specifically"
            },
            {
              "drug_name": "Rituximab",
              "drug_class": "CD20 monoclonal antibody",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "Used off-label as second-line treatment for TA-TMA, but not FDA-approved for transplantation-associated TMA specifically"
            }
          ],
          "approved_drug_names": [],
          "num_approved_drugs": 0,
          "num_pipeline_therapies": 2,
          "pipeline_therapies": [
            {
              "drug_name": "ravulizumab (Ultomiris)",
              "company": "AstraZeneca",
              "mechanism": "C5 complement inhibitor",
              "phase": "Phase 3",
              "trial_id": "ALXN1210-TMA-314",
              "expected_completion": null
            },
            {
              "drug_name": "defibrotide",
              "company": null,
              "mechanism": null,
              "phase": "Phase 3",
              "trial_id": "NCT03384693",
              "expected_completion": null
            }
          ],
          "pipeline_details": "The transplantation-associated thrombotic microangiopathy pipeline includes ravulizumab in Phase 3 trials for pediatric patients and defibrotide in prophylaxis trials. Multiple therapeutic agents are being tested in ongoing clinical trials targeting this high mortality condition.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "First-line treatment focuses on identifying and removing triggering causes with supportive care including discontinuation of calcineurin inhibitors. Second-line treatments include plasma exchange, complement inhibitors like eculizumab, rituximab, and defibrotide used off-label.",
          "unmet_need": true,
          "unmet_need_description": "No FDA-approved treatments specifically for transplantation-associated thrombotic microangiopathy exist, with mortality rates of 50-90%. Current treatment relies on supportive care and off-label use of therapies approved for other conditions.",
          "competitive_landscape": "The field represents a significant unmet medical need with no FDA-approved branded innovative treatments for TA-TMA specifically. Nomacopan has orphan designation but is not yet FDA-approved, while current therapies like eculizumab are used off-label based on complement pathway involvement.",
          "soc_source": "Frontiers in Immunology and Nature Reviews"
        },
        "market_size_estimate": "$576M",
        "market_size_usd": 576000000.0,
        "growth_rate": "5-8% CAGR (high unmet need)",
        "tam_usd": 172800000.0,
        "tam_estimate": "$172.8M",
        "tam_rationale": "Of 2,880 global TA-TMA patients, ~80% are diagnosed (2,304), ~90% receive treatment given high severity (2,074). With no approved drugs and high mortality, a new targeted therapy could capture 40-50% market share (~900 patients). At $192K/yr pricing (similar to complement inhibitor eculizumab used off-label), TAM = $172.8M. Ultra-rare orphan indication with high unmet need supports premium pricing and strong penetration.",
        "tam_sources": [
          "https://www.openpr.com/news/4007899/thrombotic-microangiopathy-treatment-market-size-in-7mm",
          "https://www.nature.com/articles/s41409-021-01283-0",
          "https://www.astctjournal.org/article/S2666-6367(25)01226-6/fulltext"
        ],
        "pipeline_sources": [
          "https://www.astrazeneca.com/content/astraz/media-centre/medical-releases/ultomiris-ravulizumab-meaningful-survival-87-at-26-weeks-children-thrombotic-mp-after-haematopoietic-stem-cell-transplant-phase-iii-open-label-trial.html",
          "http://clinicaltrials.gov/show/NCT03384693",
          "https://www.astctjournal.org/article/S2666-6367(25)01226-6/fulltext"
        ],
        "attributed_sources": [
          {
            "url": "https://www.astctjournal.org/article/S2666-6367(22)00029-X/fulltext",
            "title": "Incidence and Risk Factors of Transplantation-Associated ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://pubmed.ncbi.nlm.nih.gov/35042011/",
            "title": "Incidence and Risk Factors of Transplantation-Associated ... - PubMed",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=698219",
            "title": "Search Orphan Drug Designations and Approvals - FDA",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://cme.medscape.com/viewarticle/999440_2",
            "title": "Optimizing Care for Patients With aHUS, HSCT-TMA, and ...",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1583506/full",
            "title": "Successful treatment of transplant-associated thrombotic ... - Frontiers",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://www.astrazeneca.com/content/astraz/media-centre/medical-releases/ultomiris-ravulizumab-meaningful-survival-87-at-26-weeks-children-thrombotic-mp-after-haematopoietic-stem-cell-transplant-phase-iii-open-label-trial.html",
            "title": "Ultomiris (ravulizumab) demonstrated clinically meaningful ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "http://clinicaltrials.gov/show/NCT03384693",
            "title": "NCT03384693 | Defibrotide TMA Prophylaxis Pilot Trial",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.openpr.com/news/4007899/thrombotic-microangiopathy-treatment-market-size-in-7mm",
            "title": "Thrombotic Microangiopathy Treatment Market Size in 7MM",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://www.nature.com/articles/s41409-021-01283-0",
            "title": "Transplant-associated thrombotic microangiopathy - Nature",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 9.0,
        "evidence_quality": 6.6,
        "market_opportunity": 9.0,
        "overall_priority": 8.4,
        "clinical_breakdown": {
          "response_rate_quality_weighted": 8.9,
          "safety_profile": 8.5,
          "organ_domain_breadth": 10.0,
          "safety_categories": [
            "cardiovascular",
            "non_serious_infection",
            "thromboembolic",
            "neurological"
          ],
          "regulatory_flags": [
            "cardiovascular",
            "thromboembolic"
          ],
          "efficacy_endpoint_count": 16,
          "efficacy_concordance": 1.1
        },
        "response_rate_score": 8.9,
        "safety_profile_score": 8.5,
        "endpoint_quality_score": null,
        "organ_domain_score": 10.0,
        "evidence_breakdown": {
          "sample_size": 2.0,
          "publication_venue": 10.0,
          "response_durability": 9.0,
          "extraction_completeness": 7.8
        },
        "sample_size_score": 2.0,
        "publication_venue_score": 10.0,
        "followup_duration_score": 9.0,
        "extraction_completeness_score": 7.8,
        "market_breakdown": {
          "competitors": 10.0,
          "market_size": 7.0,
          "unmet_need": 10.0
        },
        "competitors_score": 10.0,
        "market_size_score": 7.0,
        "unmet_need_score": 10.0
      },
      "rank": 1
    },
    {
      "extraction": {
        "source": {
          "pmid": "39118827",
          "doi": "10.1159/000540013",
          "url": "https://pubmed.ncbi.nlm.nih.gov/39118827/",
          "title": "First Successful Treatment of a Patient with a Primary Immune Complex-Membranoproliferative Glomerulonephritis with Iptacopan: A Case Report.",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Peer-reviewed journal",
          "is_open_access": false
        },
        "disease": "Primary Immune Complex-Membranoproliferative Glomerulonephritis",
        "disease_normalized": "Membranoproliferative Glomerulonephritis",
        "is_off_label": true,
        "is_relevant": true,
        "evidence_level": "Case Report",
        "patient_population": {
          "n_patients": 1,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "prednisone",
            "mycophenolate mofetil",
            "tacrolimus"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "47-year-old male with primary immune complex-MPGN, baseline eGFR 42 mL/min/1.73m2, nephrotic range proteinuria"
        },
        "treatment": {
          "drug_name": "iptacopan",
          "generic_name": "iptacopan",
          "mechanism": "Iptacopan binds to Factor B of the alternative complement pathway and regulates the cleavage of C3, generation of downstream effectors, and the amplification of the terminal pathway. In PNH, intravascular hemolysis (IVH) is mediated by the downstream membrane attack complex (MAC), while extravascular hemolysis (EVH) is facilitated by C3b opsonization. Iptacopan acts proximally in the alternative pathway of the complement cascade to control both C3b-mediated EVH and terminal complement-mediated IVH. In IgAN, the deposition of galactose deficient IgA1 (Gd-IgA1) containing immune complexes in the kidney locally activates the alternative complement pathway which is thought to contribute to the pathogenesis of IgAN. By binding to Factor B, iptacopan inhibits the alternative pathway. In C3G, overactivation of the alternative complement pathway leads to C3 cleavage within the glomeruli resulting in C3 deposition and inflammation, which are thought to contribute to the pathogenesis of C3G. By ",
          "target": null,
          "route_of_administration": "oral",
          "dose": "200 mg BID",
          "frequency": null,
          "duration": "6+ months",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": null,
          "responders_n": 1,
          "responders_pct": 100.0,
          "time_to_response": "3 months",
          "duration_of_response": "ongoing at 6+ months",
          "effect_size_description": "dramatic reduction in proteinuria with stabilization of kidney function",
          "primary_endpoint": "urine protein-creatinine ratio reduction",
          "endpoint_result": "UPCR decreased from 1,370 mg/mmol to 100-150 mg/mmol at 3 months",
          "durability_signal": null,
          "efficacy_summary": "UPCR decreased impressively from nephrotic range (1,370 mg/mmol) to near-normal levels (100-150 mg/mmol) within 3 months of iptacopan treatment. Kidney function returned to baseline and remained stable during 6+ months follow-up."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": null,
          "sae_percentage": null,
          "discontinuations_n": 0,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "Iptacopan was well tolerated with no adverse side effects reported during 6+ months of treatment. Patient particularly appreciated the steroid-sparing therapy given previous serious side effects from prednisone.",
          "safety_profile": "Favorable"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Strong",
        "comparator_baseline": null,
        "follow_up_duration": "6+ months",
        "key_findings": "First reported case of successful treatment of primary immune complex-MPGN with iptacopan, achieving dramatic proteinuria reduction and stable kidney function after failure of conventional immunosuppressive therapies.",
        "detailed_efficacy_endpoints": [
          {
            "endpoint_name": "Urine protein-creatinine ratio (UPCR)",
            "endpoint_category": "Primary",
            "timepoint": "3 months post-iptacopan",
            "measurement_type": "Absolute value",
            "value": 125.0,
            "unit": "mg/mmol",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 1370.0,
            "final_value": 125.0,
            "change_from_baseline": -1245.0,
            "change_pct": -90.9,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Range given as 100-150 mg/mmol, using midpoint; baseline from peak during flare before iptacopan",
            "organ_domain": "Renal",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "Estimated glomerular filtration rate (eGFR)",
            "endpoint_category": "Primary",
            "timepoint": "3 months post-iptacopan",
            "measurement_type": "Absolute value",
            "value": 50.0,
            "unit": "mL/min/1.73 m\u00b2",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 30.0,
            "final_value": 50.0,
            "change_from_baseline": 20.0,
            "change_pct": 66.7,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Returned to baseline level; baseline refers to pre-flare stable level",
            "organ_domain": "Renal",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "Serum creatinine",
            "endpoint_category": "Secondary",
            "timepoint": "During acute flare pre-iptacopan",
            "measurement_type": "Absolute value",
            "value": 200.0,
            "unit": "\u03bcmol/L",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 172.0,
            "final_value": null,
            "change_from_baseline": 28.0,
            "change_pct": 16.3,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Peak level during acute kidney failure before iptacopan treatment",
            "organ_domain": "Renal",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "Alternative complement pathway activity",
            "endpoint_category": "Secondary",
            "timepoint": "Monthly monitoring post-iptacopan",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "total_n": 1,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Complete blockade of alternative complement cascade confirmed",
            "organ_domain": "Immunological",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "Disease remission",
            "endpoint_category": "Primary",
            "timepoint": "6 months post-iptacopan",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "total_n": 1,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Patient maintained on iptacopan monotherapy with stable low proteinuria and kidney function",
            "organ_domain": "Renal",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Time to proteinuria response",
            "endpoint_category": "Secondary",
            "timepoint": "3 months",
            "measurement_type": "Absolute value",
            "value": 3.0,
            "unit": "months",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Time to impressive decrease in UPCR after starting iptacopan",
            "organ_domain": "Renal",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          }
        ],
        "detailed_safety_endpoints": [],
        "extraction_timestamp": "2025-12-08T00:13:01.299517",
        "extraction_confidence": 0.6,
        "extraction_confidence_detail": null,
        "extraction_method": "multi_stage",
        "extraction_stages_completed": [
          "section_identification",
          "efficacy_extraction",
          "safety_extraction"
        ],
        "data_sections_identified": {
          "baseline_tables": [
            "Table 1: Kidney biopsy findings - contains detailed histopathological findings including light microscopy, immunofluorescence, and electron microscopy results showing immune complex-MPGN pattern"
          ],
          "efficacy_tables": [],
          "safety_tables": [],
          "efficacy_figures": [
            "Figure 2: Course of the successful treatment showing urine protein-creatinine ratio (UPCR) over time from 2017-2023, demonstrating dramatic reduction from >1000 mg/mmol to 100-150 mg/mmol after iptacopan treatment"
          ],
          "results_sections": [
            "Case Presentation section detailing the complete clinical course",
            "Discussion section summarizing treatment outcomes"
          ],
          "patient_count": 1,
          "study_type": "Case Report",
          "has_quantitative_outcomes": true,
          "notes": "Single patient case report showing dramatic proteinuria reduction (UPCR from >1000 mg/mmol to 100-150 mg/mmol) within 3 months of iptacopan treatment. eGFR improved from 30 to baseline ~50 mL/min/1.73m2. No formal efficacy or safety tables - outcomes presented in figure and text descriptions."
        }
      },
      "market_intelligence": {
        "disease": "Membranoproliferative Glomerulonephritis",
        "epidemiology": {
          "us_prevalence_estimate": "4.6-6.6 per 100,000 individuals",
          "us_incidence_estimate": "1.4 to 9.3 cases per million population per year",
          "global_prevalence": null,
          "patient_population_size": 18590,
          "prevalence_source": "WikiDoc",
          "prevalence_source_url": "https://www.wikidoc.org/index.php/Membranoproliferative_glomerulonephritis_epidemiology_and_demographics",
          "trend": null,
          "source_quality": "Secondary",
          "data_year": null,
          "geographic_scope": "Global",
          "confidence": "Medium",
          "notes": "Prevalence range of 4.6-6.6 per 100,000 worldwide used to estimate US population; represents 6-12% of kidney biopsies for glomerular diseases in US; accounts for 7% of children and 12% of adults with idiopathic nephrotic syndrome"
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Empaveli (pegcetacoplan)",
              "drug_class": "Complement C3 inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "primary immune complex membranoproliferative glomerulonephritis (IC-MPGN)",
              "efficacy_range": "68% reduction in proteinuria",
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "First FDA-approved treatment for primary IC-MPGN. Also approved for C3 glomerulopathy. Approved for adult and pediatric patients aged 12 years and older. Shows 71% of patients achieved zero C3 staining intensity."
            }
          ],
          "approved_drug_names": [
            "Empaveli (pegcetacoplan)"
          ],
          "num_approved_drugs": 1,
          "num_pipeline_therapies": 3,
          "pipeline_therapies": [
            {
              "drug_name": "ALXN2040",
              "company": "Alexion Pharmaceuticals",
              "mechanism": null,
              "phase": "Phase 2",
              "trial_id": "NCT03459443",
              "expected_completion": null
            },
            {
              "drug_name": "iptacopan",
              "company": null,
              "mechanism": null,
              "phase": "Phase 3",
              "trial_id": "NCT05755386",
              "expected_completion": null
            },
            {
              "drug_name": "pegcetacoplan",
              "company": null,
              "mechanism": null,
              "phase": "Phase 3",
              "trial_id": "NCT05067127",
              "expected_completion": null
            }
          ],
          "pipeline_details": "Three therapies are in active clinical trials for membranoproliferative glomerulonephritis: ALXN2040 in Phase 2 testing and both iptacopan and pegcetacoplan advancing to Phase 3 studies. The pipeline focuses on complement pathway modulation for treating this rare kidney disease.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "First-line treatment with Empaveli (pegcetacoplan) as the only FDA-approved specific therapy for primary IC-MPGN, targeting complement C3 to reduce proteinuria and stabilize kidney function.",
          "unmet_need": false,
          "unmet_need_description": "Recently addressed with FDA approval of Empaveli in 2025 as the first specific treatment for this indication",
          "competitive_landscape": "Empaveli currently represents the only FDA-approved branded innovative treatment specifically for primary IC-MPGN. Previously, treatment relied on off-label use of immunosuppressive agents like rituximab, steroids, and cyclophosphamide.",
          "soc_source": "FDA Approves Empaveli for Rare Kidney Diseases - https://www.drugs.com/news/fda-approves-empaveli-rare-kidney-diseases-126076.html"
        },
        "market_size_estimate": "$1.9B",
        "market_size_usd": 1859000000.0,
        "growth_rate": "3-5% CAGR (estimated)",
        "tam_usd": 114300000.0,
        "tam_estimate": "$114.3M",
        "tam_rationale": "Of ~18,590 US patients with MPGN, ~70% are diagnosed (13,013), ~80% receive treatment given the severe nature of the disease (10,410). With only one approved specific therapy (Empaveli), a new drug entering as 1L competition or 2L after Empaveli failure could capture 30-40% market share (~3,500 patients). At $32,500/yr (typical orphan drug pricing for complement-mediated kidney diseases), TAM = $113.8M. Strong opportunity exists given limited treatment options in this rare complement-driven nephropathy.",
        "tam_sources": [
          "https://www.novartis.com/sites/novartiscom/files/q4-2022-investor-presentation.pdf",
          "https://pmc.ncbi.nlm.nih.gov/articles/PMC7758461/",
          "https://www.investing.com/news/transcripts/earnings-call-transcript-apellis-pharmaceuticals-q2-2025-beats-eps-forecast-stock-surges-93CH-4204795"
        ],
        "pipeline_sources": [
          "https://cdn.clinicaltrials.gov/large-docs/43/NCT03459443/SAP_002.pdf",
          "https://pmc.ncbi.nlm.nih.gov/articles/PMC11309753/",
          "https://www.clinicaltrials.gov/study/nct05067127"
        ],
        "attributed_sources": [
          {
            "url": "https://emedicine.medscape.com/article/240056-overview",
            "title": "Membranoproliferative Glomerulonephritis - Medscape Reference",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.wikidoc.org/index.php/Membranoproliferative_glomerulonephritis_epidemiology_and_demographics",
            "title": "Membranoproliferative glomerulonephritis epidemiology ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.drugs.com/news/fda-approves-empaveli-rare-kidney-diseases-126076.html",
            "title": "FDA Approves Empaveli for Rare Kidney Diseases",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.drugs.com/history/empaveli.html",
            "title": "Empaveli (pegcetacoplan) FDA Approval History",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://emedicine.medscape.com/article/240056-treatment",
            "title": "Membranoproliferative Glomerulonephritis Treatment & Management",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://cdn.clinicaltrials.gov/large-docs/43/NCT03459443/SAP_002.pdf",
            "title": "An Open- Label Phase 2 Proof -of-Concept Study in Patients ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11309753/",
            "title": "First Successful Treatment of a Patient with a Primary ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.novartis.com/sites/novartiscom/files/q4-2022-investor-presentation.pdf",
            "title": "[PDF] Q4 2022 Results - Investor presentation - Novartis",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7758461/",
            "title": "Treatment of Rare Inflammatory Kidney Diseases",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 8.5,
        "evidence_quality": 4.9,
        "market_opportunity": 7.7,
        "overall_priority": 7.4,
        "clinical_breakdown": {
          "response_rate_quality_weighted": 7.3,
          "safety_profile": 9.0,
          "organ_domain_breadth": 10.0,
          "safety_categories": [],
          "regulatory_flags": [],
          "efficacy_endpoint_count": 6,
          "efficacy_concordance": 0.9
        },
        "response_rate_score": 7.3,
        "safety_profile_score": 9.0,
        "endpoint_quality_score": null,
        "organ_domain_score": 10.0,
        "evidence_breakdown": {
          "sample_size": 1.0,
          "publication_venue": 10.0,
          "response_durability": 4.0,
          "extraction_completeness": 7.2
        },
        "sample_size_score": 1.0,
        "publication_venue_score": 10.0,
        "followup_duration_score": 4.0,
        "extraction_completeness_score": 7.2,
        "market_breakdown": {
          "competitors": 7.0,
          "market_size": 8.0,
          "unmet_need": 8.0
        },
        "competitors_score": 7.0,
        "market_size_score": 8.0,
        "unmet_need_score": 8.0
      },
      "rank": 2
    },
    {
      "extraction": {
        "source": {
          "pmid": "40115776",
          "doi": "10.3389/fmed.2025.1551042",
          "url": "https://pubmed.ncbi.nlm.nih.gov/40115776/",
          "title": "The treatment of autoimmune hemolytic anemia with complement inhibitor iptacopan: a case report.",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Peer-reviewed journal",
          "is_open_access": false
        },
        "disease": "autoimmune hemolytic anemia (warm antibody type)",
        "disease_normalized": "Autoimmune Hemolytic Anemia",
        "is_off_label": true,
        "is_relevant": true,
        "evidence_level": "Case Report",
        "patient_population": {
          "n_patients": 1,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "methylprednisolone",
            "intravenous immunoglobulin"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "60-year-old male with acute severe warm antibody autoimmune hemolytic anemia presenting with hemolytic crisis"
        },
        "treatment": {
          "drug_name": "iptacopan",
          "generic_name": "iptacopan",
          "mechanism": "Iptacopan binds to Factor B of the alternative complement pathway and regulates the cleavage of C3, generation of downstream effectors, and the amplification of the terminal pathway. In PNH, intravascular hemolysis (IVH) is mediated by the downstream membrane attack complex (MAC), while extravascular hemolysis (EVH) is facilitated by C3b opsonization. Iptacopan acts proximally in the alternative pathway of the complement cascade to control both C3b-mediated EVH and terminal complement-mediated IVH. In IgAN, the deposition of galactose deficient IgA1 (Gd-IgA1) containing immune complexes in the kidney locally activates the alternative complement pathway which is thought to contribute to the pathogenesis of IgAN. By binding to Factor B, iptacopan inhibits the alternative pathway. In C3G, overactivation of the alternative complement pathway leads to C3 cleavage within the glomeruli resulting in C3 deposition and inflammation, which are thought to contribute to the pathogenesis of C3G. By ",
          "target": null,
          "route_of_administration": "oral",
          "dose": "200 mg twice daily",
          "frequency": null,
          "duration": "15 days",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "1/1 (100%)",
          "responders_n": 1,
          "responders_pct": 100.0,
          "time_to_response": "after day 6 of hospitalization",
          "duration_of_response": "maintained through 15-day treatment period and follow-up",
          "effect_size_description": "hemoglobin increased by 46 g/L, LDH decreased from 1295 to 489 IU/L, indirect bilirubin decreased from 162 to 24.5 \u03bcmol/L",
          "primary_endpoint": "hemoglobin level improvement",
          "endpoint_result": "hemoglobin increased from 31 g/L to 77 g/L",
          "durability_signal": null,
          "efficacy_summary": "Patient showed rapid improvement in hemolytic crisis with normalization of hemolysis markers and elimination of transfusion requirement. Clinical symptoms including fatigue, jaundice, and dark urine significantly improved within days of iptacopan initiation."
        },
        "safety": {
          "adverse_events": [
            "transient thrombocytopenia"
          ],
          "serious_adverse_events": [],
          "sae_count": 0,
          "sae_percentage": 0.0,
          "discontinuations_n": 0,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "Patient experienced transient decrease in platelet count attributed to iptacopan, which normalized by day 14 of treatment. No serious adverse events or treatment discontinuations occurred during the 15-day treatment period.",
          "safety_profile": "Acceptable"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Strong",
        "comparator_baseline": null,
        "follow_up_duration": "1 month post-discharge",
        "key_findings": "First reported use of iptacopan for autoimmune hemolytic anemia showing rapid resolution of hemolytic crisis and sustained improvement in hemolysis markers. Combination with glucocorticoids eliminated transfusion requirement and normalized laboratory parameters.",
        "detailed_efficacy_endpoints": [
          {
            "endpoint_name": "Hemoglobin level",
            "endpoint_category": "Primary",
            "timepoint": "Day 15",
            "measurement_type": "Absolute value",
            "value": 77.0,
            "unit": "g/L",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 47.0,
            "final_value": 77.0,
            "change_from_baseline": 30.0,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Improvement from presentation to day 15 of treatment",
            "organ_domain": "Hematological",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "Lactate dehydrogenase",
            "endpoint_category": "Secondary",
            "timepoint": "Day 15",
            "measurement_type": "Absolute value",
            "value": 489.0,
            "unit": "IU/L",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 1295.0,
            "final_value": 489.0,
            "change_from_baseline": -806.0,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Marker of hemolysis - significant improvement",
            "organ_domain": "Hematological",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "Indirect bilirubin",
            "endpoint_category": "Secondary",
            "timepoint": "Day 15",
            "measurement_type": "Absolute value",
            "value": 24.5,
            "unit": "\u03bcmol/L",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 162.0,
            "final_value": 24.5,
            "change_from_baseline": -137.5,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Marker of hemolysis - significant improvement",
            "organ_domain": "Hematological",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "Reticulocyte percentage",
            "endpoint_category": "Secondary",
            "timepoint": "Day 15",
            "measurement_type": "Absolute value",
            "value": 13.51,
            "unit": "%",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 3.18,
            "final_value": 13.51,
            "change_from_baseline": 10.33,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Increased reticulocyte production as response to hemolysis",
            "organ_domain": "Hematological",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "Reticulocyte absolute count",
            "endpoint_category": "Secondary",
            "timepoint": "Day 15",
            "measurement_type": "Absolute value",
            "value": 280.0,
            "unit": "\u00d710^9/L",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 30.0,
            "final_value": 280.0,
            "change_from_baseline": 250.0,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Increased reticulocyte production as response to hemolysis",
            "organ_domain": "Hematological",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "White blood cell count",
            "endpoint_category": "Secondary",
            "timepoint": "Day 15",
            "measurement_type": "Absolute value",
            "value": null,
            "unit": "\u00d710^9/L",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 15.95,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Normalized by day 15, exact value not specified",
            "organ_domain": "Hematological",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "Neutrophil count",
            "endpoint_category": "Secondary",
            "timepoint": "Day 8",
            "measurement_type": "Absolute value",
            "value": null,
            "unit": "\u00d710^9/L",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 13.95,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Returned to normal range by day 8, exact value not specified",
            "organ_domain": "Hematological",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "Platelet count",
            "endpoint_category": "Secondary",
            "timepoint": "Day 15",
            "measurement_type": "Absolute value",
            "value": null,
            "unit": "\u00d710^9/L",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 125.0,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Normalized by day 15, exact value not specified",
            "organ_domain": "Hematological",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "Hemoglobin level",
            "endpoint_category": "Primary",
            "timepoint": "5 days post-discharge",
            "measurement_type": "Absolute value",
            "value": 74.0,
            "unit": "g/L",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 47.0,
            "final_value": 74.0,
            "change_from_baseline": 27.0,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Sustained improvement after discharge",
            "organ_domain": "Hematological",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "Lactate dehydrogenase",
            "endpoint_category": "Secondary",
            "timepoint": "5 days post-discharge",
            "measurement_type": "Absolute value",
            "value": 391.2,
            "unit": "IU/L",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 1295.0,
            "final_value": 391.2,
            "change_from_baseline": -903.8,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Continued improvement in hemolysis marker",
            "organ_domain": "Hematological",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "Reticulocyte percentage",
            "endpoint_category": "Secondary",
            "timepoint": "5 days post-discharge",
            "measurement_type": "Absolute value",
            "value": 8.0,
            "unit": "%",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 3.18,
            "final_value": 8.0,
            "change_from_baseline": 4.82,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Decrease from peak levels during treatment",
            "organ_domain": "Hematological",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "Total bilirubin",
            "endpoint_category": "Secondary",
            "timepoint": "5 days post-discharge",
            "measurement_type": "Absolute value",
            "value": 42.5,
            "unit": "\u03bcmol/L",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 183.0,
            "final_value": 42.5,
            "change_from_baseline": -140.5,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Significant improvement in hemolysis marker",
            "organ_domain": "Hematological",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "Indirect bilirubin",
            "endpoint_category": "Secondary",
            "timepoint": "5 days post-discharge",
            "measurement_type": "Absolute value",
            "value": 34.8,
            "unit": "\u03bcmol/L",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 162.0,
            "final_value": 34.8,
            "change_from_baseline": -127.2,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Significant improvement in hemolysis marker",
            "organ_domain": "Hematological",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "Reticulocyte percentage",
            "endpoint_category": "Secondary",
            "timepoint": "1 month post-discharge",
            "measurement_type": "Absolute value",
            "value": 1.1,
            "unit": "%",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 3.18,
            "final_value": 1.1,
            "change_from_baseline": -2.08,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Near normal levels, indicating stabilization",
            "organ_domain": "Hematological",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "Reticulocyte absolute count",
            "endpoint_category": "Secondary",
            "timepoint": "1 month post-discharge",
            "measurement_type": "Absolute value",
            "value": 29.0,
            "unit": "\u00d710^9/L",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 30.0,
            "final_value": 29.0,
            "change_from_baseline": -1.0,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Return to baseline levels, indicating disease stabilization",
            "organ_domain": "Hematological",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "Blood transfusion requirement",
            "endpoint_category": "Primary",
            "timepoint": "After day 6",
            "measurement_type": "Responder",
            "value": 1.0,
            "unit": "patient",
            "total_n": 1,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Complete cessation of transfusion requirement after day 6",
            "organ_domain": "Hematological",
            "is_validated_instrument": true,
            "instrument_quality_tier": 1
          },
          {
            "endpoint_name": "Clinical improvement in fatigue",
            "endpoint_category": "Secondary",
            "timepoint": "After day 6",
            "measurement_type": "Responder",
            "value": 1.0,
            "unit": "patient",
            "total_n": 1,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Significant alleviation of fatigue reported",
            "organ_domain": "Constitutional",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Clinical improvement in jaundice",
            "endpoint_category": "Secondary",
            "timepoint": "After day 6",
            "measurement_type": "Responder",
            "value": 1.0,
            "unit": "patient",
            "total_n": 1,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Marked reduction in skin jaundice reported",
            "organ_domain": "Hematological",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          }
        ],
        "detailed_safety_endpoints": [
          {
            "event_name": "Thrombocytopenia",
            "event_category": "AE",
            "severity_grade": "Mild",
            "patients_affected_n": 1,
            "patients_affected_pct": null,
            "events_total": 1,
            "relatedness": "Related",
            "outcome": "Resolved",
            "action_taken": "None",
            "notes": "Transient decrease in platelet count following iptacopan administration, near normal on day 12, returned to normal by day 14 of iptacopan therapy",
            "category_soc": "Cytopenias",
            "infection_type": null,
            "malignancy_type": null,
            "cv_type": null,
            "thromboembolic_type": null,
            "is_class_effect": false
          },
          {
            "event_name": "Headache",
            "event_category": "AE",
            "severity_grade": null,
            "patients_affected_n": null,
            "patients_affected_pct": null,
            "events_total": null,
            "relatedness": "Related",
            "outcome": null,
            "action_taken": null,
            "notes": "Most common adverse event associated with iptacopan in general literature",
            "category_soc": "Neurological",
            "infection_type": null,
            "malignancy_type": null,
            "cv_type": null,
            "thromboembolic_type": null,
            "is_class_effect": false
          },
          {
            "event_name": "Abdominal discomfort",
            "event_category": "AE",
            "severity_grade": null,
            "patients_affected_n": null,
            "patients_affected_pct": null,
            "events_total": null,
            "relatedness": "Related",
            "outcome": null,
            "action_taken": null,
            "notes": "Most common adverse event associated with iptacopan in general literature",
            "category_soc": "GI Perforation",
            "infection_type": null,
            "malignancy_type": null,
            "cv_type": null,
            "thromboembolic_type": null,
            "is_class_effect": false
          },
          {
            "event_name": "Infections",
            "event_category": "AE",
            "severity_grade": null,
            "patients_affected_n": null,
            "patients_affected_pct": null,
            "events_total": null,
            "relatedness": "Related",
            "outcome": null,
            "action_taken": null,
            "notes": "Most common adverse event associated with iptacopan in general literature",
            "category_soc": "Infections",
            "infection_type": null,
            "malignancy_type": null,
            "cv_type": null,
            "thromboembolic_type": null,
            "is_class_effect": false
          },
          {
            "event_name": "Thrombocytopenia",
            "event_category": "AE",
            "severity_grade": null,
            "patients_affected_n": 2,
            "patients_affected_pct": 20.0,
            "events_total": null,
            "relatedness": "Related",
            "outcome": null,
            "action_taken": null,
            "notes": "Previous clinical trial data: thrombocytopenia in 20% of 10 patients treated with iptacopan",
            "category_soc": "Cytopenias",
            "infection_type": null,
            "malignancy_type": null,
            "cv_type": null,
            "thromboembolic_type": null,
            "is_class_effect": false
          },
          {
            "event_name": "Any adverse event",
            "event_category": "AE",
            "severity_grade": "Mild",
            "patients_affected_n": 9,
            "patients_affected_pct": 90.0,
            "events_total": null,
            "relatedness": "Related",
            "outcome": null,
            "action_taken": null,
            "notes": "Previous clinical trial data: 90% of patients experienced at least one adverse event, typically mild in severity",
            "category_soc": null,
            "infection_type": null,
            "malignancy_type": null,
            "cv_type": null,
            "thromboembolic_type": null,
            "is_class_effect": false
          },
          {
            "event_name": "Thrombocytopenia",
            "event_category": "AE",
            "severity_grade": null,
            "patients_affected_n": 3,
            "patients_affected_pct": 5.0,
            "events_total": null,
            "relatedness": "Related",
            "outcome": null,
            "action_taken": null,
            "notes": "APPLY-PNH trial data: thrombocytopenia observed in 5% of 62 patients",
            "category_soc": "Cytopenias",
            "infection_type": null,
            "malignancy_type": null,
            "cv_type": null,
            "thromboembolic_type": null,
            "is_class_effect": false
          },
          {
            "event_name": "Serious adverse events",
            "event_category": "SAE",
            "severity_grade": null,
            "patients_affected_n": 6,
            "patients_affected_pct": 10.0,
            "events_total": null,
            "relatedness": null,
            "outcome": null,
            "action_taken": null,
            "notes": "APPLY-PNH trial data: serious adverse events occurred in 10% of patients, no patients discontinued treatment due to adverse events",
            "category_soc": null,
            "infection_type": null,
            "malignancy_type": null,
            "cv_type": null,
            "thromboembolic_type": null,
            "is_class_effect": false
          },
          {
            "event_name": "Lung infection",
            "event_category": "AE",
            "severity_grade": null,
            "patients_affected_n": 1,
            "patients_affected_pct": null,
            "events_total": 1,
            "relatedness": "Unrelated",
            "outcome": "Ongoing",
            "action_taken": "None",
            "notes": "Developed in case patient during follow-up due to prolonged history of hormone use, managed with anti-infective therapy",
            "category_soc": "Infections",
            "infection_type": "Bacterial",
            "malignancy_type": null,
            "cv_type": null,
            "thromboembolic_type": null,
            "is_class_effect": false
          },
          {
            "event_name": "Osteoporosis",
            "event_category": "AE",
            "severity_grade": null,
            "patients_affected_n": 1,
            "patients_affected_pct": null,
            "events_total": 1,
            "relatedness": "Unrelated",
            "outcome": "Ongoing",
            "action_taken": "None",
            "notes": "Developed in case patient during follow-up due to prolonged history of hormone use, managed with calcium supplementation",
            "category_soc": "Metabolic",
            "infection_type": null,
            "malignancy_type": null,
            "cv_type": null,
            "thromboembolic_type": null,
            "is_class_effect": false
          }
        ],
        "extraction_timestamp": "2025-12-08T00:16:00.610966",
        "extraction_confidence": 0.6,
        "extraction_confidence_detail": null,
        "extraction_method": "multi_stage",
        "extraction_stages_completed": [
          "section_identification",
          "efficacy_extraction",
          "safety_extraction"
        ],
        "data_sections_identified": {
          "baseline_tables": [],
          "efficacy_tables": [],
          "safety_tables": [],
          "efficacy_figures": [
            "FIGURE 1: Laboratory parameters over time including WBC count, neutrophil count, hemoglobin, platelet count, total bilirubin, and indirect bilirubin",
            "FIGURE 2: Reticulocyte percentage, absolute reticulocyte count, and lactate dehydrogenase over time"
          ],
          "results_sections": [
            "Case presentation",
            "Follow up"
          ],
          "patient_count": 1,
          "study_type": "Case Report",
          "has_quantitative_outcomes": true,
          "notes": "Single case report with detailed laboratory monitoring data presented in figures rather than tables. Shows treatment response to iptacopan with comprehensive lab parameter tracking over 15 days of hospitalization plus follow-up data."
        }
      },
      "market_intelligence": {
        "disease": "Autoimmune Hemolytic Anemia",
        "epidemiology": {
          "us_prevalence_estimate": "5.2 to 23.0 per 100,000 persons",
          "us_incidence_estimate": "1.4 to 6.6 per 100,000 persons annually",
          "global_prevalence": null,
          "patient_population_size": 47850,
          "prevalence_source": "PLoS ONE",
          "prevalence_source_url": "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0323843",
          "trend": null,
          "source_quality": "Primary",
          "data_year": 2023,
          "geographic_scope": "US",
          "confidence": "High",
          "notes": "Wide range reported across three databases (Optum CDM, Inovalon, Medicare FFS); point prevalence varies significantly by geographic region and database used"
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Sutimlimab (BIVV009)",
              "drug_class": "C1s complement inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Cold Agglutinin Disease",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "FDA-approved for cold agglutinin disease subtype of autoimmune hemolytic anemia; humanized IgG4 monoclonal antibody targeting complement component C1s"
            },
            {
              "drug_name": "Rituximab",
              "drug_class": "CD20 monoclonal antibody",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "Not FDA-approved specifically for autoimmune hemolytic anemia but widely used off-label as second-line therapy"
            },
            {
              "drug_name": "Fludarabine Phosphate",
              "drug_class": "Antimetabolite",
              "is_branded_innovative": false,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": null,
              "notes": "FDA label mentions autoimmune hemolytic anemia as adverse reaction, not approved for treatment of condition"
            }
          ],
          "approved_drug_names": [
            "Sutimlimab (BIVV009)"
          ],
          "num_approved_drugs": 1,
          "num_pipeline_therapies": 1,
          "pipeline_therapies": [
            {
              "drug_name": "Fostamatinib",
              "company": null,
              "mechanism": "SYK inhibitor",
              "phase": "Phase 3",
              "trial_id": null,
              "expected_completion": null
            }
          ],
          "pipeline_details": "Fostamatinib, a SYK inhibitor, is currently in Phase 3 development as a randomized, double-blind, placebo-controlled global study for warm antibody autoimmune hemolytic anemia (wAIHA). The pipeline shows limited activity with only one active therapy identified specifically for autoimmune hemolytic anemia.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "First-line therapy remains corticosteroids (80% response rate), with rituximab as preferred second-line option replacing splenectomy. Sutimlimab is approved specifically for cold agglutinin disease subtype.",
          "unmet_need": true,
          "unmet_need_description": "Limited FDA-approved treatments specifically for autoimmune hemolytic anemia, with only one approved drug (sutimlimab) for a specific subtype (cold agglutinin disease). Most treatments are off-label use of drugs approved for other conditions.",
          "competitive_landscape": "The field relies heavily on off-label use of immunosuppressive agents with only sutimlimab having specific FDA approval for cold agglutinin disease. Novel treatments in development target B-cells, plasma cells, and spleen tyrosine kinase pathways.",
          "soc_source": "FDA accessdata.fda.gov and clinical literature from Medscape, PMC"
        },
        "market_size_estimate": "$4.8B",
        "market_size_usd": 4785000000.0,
        "growth_rate": "5-8% CAGR (high unmet need)",
        "tam_usd": 42000000.0,
        "tam_estimate": "$42M",
        "tam_rationale": "Of ~48K global AIHA patients, approximately 70% are diagnosed (33.5K), 60% receive systemic treatment beyond corticosteroids (20K), and 40% progress to second-line therapy (8K patients). A new drug positioned as improved 2L therapy could capture 25-30% market share (~2.1K patients). At $100K/yr pricing typical for rare autoimmune orphan drugs with high unmet need, TAM = $210M globally, with US representing ~20% or $42M.",
        "tam_sources": [
          "https://www.databridgemarketresearch.com/reports/global-autoimmune-hemolytic-anemia-treatment-market?srsltid=AfmBOooqy9l817r2cusKBqvP9M_bItTac98KmbdV0sQ8veVcFCaSklEb",
          "https://www.linkedin.com/pulse/autoimmune-hemolytic-anemia-therapeutics-market-obunc/",
          "https://www.dennisgong.com/blog/newmedicines/"
        ],
        "pipeline_sources": [
          "https://pmc.ncbi.nlm.nih.gov/articles/PMC9313871/",
          "https://www.biopharmcatalyst.com/company/IONS/news/300234",
          "https://www.biopharmcatalyst.com/news/2025/biopharmcatalyst-weekly-watchlist-key-upcoming-catalysts-due-at-ash"
        ],
        "attributed_sources": [
          {
            "url": "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0323843",
            "title": "Prevalence and incidence of primary autoimmune hemolytic anemia ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://journals.lww.com/ajg/fulltext/2020/10001/s0714_prevalence_of_autoimmune_hemolytic_anemia_in.715.aspx",
            "title": "S0714 Prevalence of Autoimmune Hemolytic Anemia in...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/761164Orig1s000AdminCorres.pdf",
            "title": "761164Orig1s000 - accessdata.fda.gov",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022137Orig1s015lbl.pdf",
            "title": "fludarabine phosphate injection - accessdata.fda.gov",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://turkarchpediatr.org/Content/files/sayilar/30/TPA_53_2_129_130%5BA%5D.pdf",
            "title": "[PDF] Current treatment options for severe autoimmune hemolytic anemia",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9313871/",
            "title": "Fostamatinib for the treatment of warm antibody ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.biopharmcatalyst.com/company/IONS/news/300234",
            "title": "Ionis presents new data demonstrating long-term disease ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.databridgemarketresearch.com/reports/global-autoimmune-hemolytic-anemia-treatment-market?srsltid=AfmBOooqy9l817r2cusKBqvP9M_bItTac98KmbdV0sQ8veVcFCaSklEb",
            "title": "Global Autoimmune Hemolytic Anemia Treatment Market Size ...",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://www.linkedin.com/pulse/autoimmune-hemolytic-anemia-therapeutics-market-obunc/",
            "title": "Autoimmune Hemolytic Anemia Therapeutics Market Size 2026",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 7.7,
        "evidence_quality": 4.8,
        "market_opportunity": 8.3,
        "overall_priority": 7.2,
        "clinical_breakdown": {
          "response_rate_quality_weighted": 7.1,
          "safety_profile": 7.2,
          "organ_domain_breadth": 10.0,
          "safety_categories": [
            "cardiovascular",
            "neurological",
            "thromboembolic",
            "cytopenia"
          ],
          "regulatory_flags": [
            "cardiovascular",
            "thromboembolic",
            "cytopenia"
          ],
          "efficacy_endpoint_count": 18,
          "efficacy_concordance": 0.9
        },
        "response_rate_score": 7.1,
        "safety_profile_score": 7.2,
        "endpoint_quality_score": null,
        "organ_domain_score": 10.0,
        "evidence_breakdown": {
          "sample_size": 1.0,
          "publication_venue": 10.0,
          "response_durability": 3.0,
          "extraction_completeness": 8.3
        },
        "sample_size_score": 1.0,
        "publication_venue_score": 10.0,
        "followup_duration_score": 3.0,
        "extraction_completeness_score": 8.3,
        "market_breakdown": {
          "competitors": 7.0,
          "market_size": 8.0,
          "unmet_need": 10.0
        },
        "competitors_score": 7.0,
        "market_size_score": 8.0,
        "unmet_need_score": 10.0
      },
      "rank": 3
    },
    {
      "extraction": {
        "source": {
          "pmid": "40853217",
          "doi": "10.1080/16078454.2025.2548091",
          "url": "https://pubmed.ncbi.nlm.nih.gov/40853217/",
          "title": "Severe hemolysis flare of refractory autoimmune hemolytic anemia with positive complement component C3d responsive to Iptacopan with cyclophosphamide and prednisone: a case report.",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Peer-reviewed journal",
          "is_open_access": false
        },
        "disease": "Autoimmune hemolytic anemia",
        "disease_normalized": "Autoimmune Hemolytic Anemia",
        "is_off_label": true,
        "is_relevant": true,
        "evidence_level": "Case Report",
        "patient_population": {
          "n_patients": 1,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": null,
          "disease_severity": null,
          "comorbidities": null,
          "description": "Patient with severe hemolysis flare of refractory autoimmune hemolytic anemia with positive complement component C3d"
        },
        "treatment": {
          "drug_name": "iptacopan",
          "generic_name": "iptacopan",
          "mechanism": "Iptacopan binds to Factor B of the alternative complement pathway and regulates the cleavage of C3, generation of downstream effectors, and the amplification of the terminal pathway. In PNH, intravascular hemolysis (IVH) is mediated by the downstream membrane attack complex (MAC), while extravascular hemolysis (EVH) is facilitated by C3b opsonization. Iptacopan acts proximally in the alternative pathway of the complement cascade to control both C3b-mediated EVH and terminal complement-mediated IVH. In IgAN, the deposition of galactose deficient IgA1 (Gd-IgA1) containing immune complexes in the kidney locally activates the alternative complement pathway which is thought to contribute to the pathogenesis of IgAN. By binding to Factor B, iptacopan inhibits the alternative pathway. In C3G, overactivation of the alternative complement pathway leads to C3 cleavage within the glomeruli resulting in C3 deposition and inflammation, which are thought to contribute to the pathogenesis of C3G. By ",
          "target": null,
          "route_of_administration": null,
          "dose": null,
          "frequency": null,
          "duration": null,
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "1/1 (100%)",
          "responders_n": 1,
          "responders_pct": 100.0,
          "time_to_response": null,
          "duration_of_response": null,
          "effect_size_description": "Patient responded to iptacopan combination therapy",
          "primary_endpoint": "Response to severe hemolytic episode",
          "endpoint_result": "Responsive to treatment combination",
          "durability_signal": null,
          "efficacy_summary": "Single patient with refractory autoimmune hemolytic anemia and positive C3d complement responded to combination therapy with iptacopan, cyclophosphamide, and prednisone during a severe hemolytic flare."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": null,
          "sae_percentage": null,
          "discontinuations_n": null,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "No safety data reported in the abstract.",
          "safety_profile": "Unknown"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Moderate",
        "comparator_baseline": null,
        "follow_up_duration": null,
        "key_findings": "Iptacopan in combination with immunosuppressive therapy showed efficacy in treating refractory autoimmune hemolytic anemia with complement involvement.",
        "detailed_efficacy_endpoints": [],
        "detailed_safety_endpoints": [],
        "extraction_timestamp": "2025-12-08T00:18:10.863332",
        "extraction_confidence": 0.5,
        "extraction_confidence_detail": null,
        "extraction_method": "single_pass",
        "extraction_stages_completed": [],
        "data_sections_identified": null
      },
      "market_intelligence": {
        "disease": "Autoimmune Hemolytic Anemia",
        "epidemiology": {
          "us_prevalence_estimate": "5.2 to 23.0 per 100,000 persons",
          "us_incidence_estimate": "1.4 to 6.6 per 100,000 persons annually",
          "global_prevalence": null,
          "patient_population_size": 47850,
          "prevalence_source": "PLoS ONE",
          "prevalence_source_url": "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0323843",
          "trend": null,
          "source_quality": "Primary",
          "data_year": 2023,
          "geographic_scope": "US",
          "confidence": "High",
          "notes": "Wide range reported across three databases (Optum CDM, Inovalon, Medicare FFS); point prevalence varies significantly by geographic region and database used"
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Sutimlimab (BIVV009)",
              "drug_class": "C1s complement inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Cold Agglutinin Disease",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "FDA-approved for cold agglutinin disease subtype of autoimmune hemolytic anemia; humanized IgG4 monoclonal antibody targeting complement component C1s"
            },
            {
              "drug_name": "Rituximab",
              "drug_class": "CD20 monoclonal antibody",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "Not FDA-approved specifically for autoimmune hemolytic anemia but widely used off-label as second-line therapy"
            },
            {
              "drug_name": "Fludarabine Phosphate",
              "drug_class": "Antimetabolite",
              "is_branded_innovative": false,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": null,
              "notes": "FDA label mentions autoimmune hemolytic anemia as adverse reaction, not approved for treatment of condition"
            }
          ],
          "approved_drug_names": [
            "Sutimlimab (BIVV009)"
          ],
          "num_approved_drugs": 1,
          "num_pipeline_therapies": 1,
          "pipeline_therapies": [
            {
              "drug_name": "Fostamatinib",
              "company": null,
              "mechanism": "SYK inhibitor",
              "phase": "Phase 3",
              "trial_id": null,
              "expected_completion": null
            }
          ],
          "pipeline_details": "Fostamatinib, a SYK inhibitor, is currently in Phase 3 development as a randomized, double-blind, placebo-controlled global study for warm antibody autoimmune hemolytic anemia (wAIHA). The pipeline shows limited activity with only one active therapy identified specifically for autoimmune hemolytic anemia.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "First-line therapy remains corticosteroids (80% response rate), with rituximab as preferred second-line option replacing splenectomy. Sutimlimab is approved specifically for cold agglutinin disease subtype.",
          "unmet_need": true,
          "unmet_need_description": "Limited FDA-approved treatments specifically for autoimmune hemolytic anemia, with only one approved drug (sutimlimab) for a specific subtype (cold agglutinin disease). Most treatments are off-label use of drugs approved for other conditions.",
          "competitive_landscape": "The field relies heavily on off-label use of immunosuppressive agents with only sutimlimab having specific FDA approval for cold agglutinin disease. Novel treatments in development target B-cells, plasma cells, and spleen tyrosine kinase pathways.",
          "soc_source": "FDA accessdata.fda.gov and clinical literature from Medscape, PMC"
        },
        "market_size_estimate": "$4.8B",
        "market_size_usd": 4785000000.0,
        "growth_rate": "5-8% CAGR (high unmet need)",
        "tam_usd": 42000000.0,
        "tam_estimate": "$42M",
        "tam_rationale": "Of ~48K global AIHA patients, approximately 70% are diagnosed (33.5K), 60% receive systemic treatment beyond corticosteroids (20K), and 40% progress to second-line therapy (8K patients). A new drug positioned as improved 2L therapy could capture 25-30% market share (~2.1K patients). At $100K/yr pricing typical for rare autoimmune orphan drugs with high unmet need, TAM = $210M globally, with US representing ~20% or $42M.",
        "tam_sources": [
          "https://www.databridgemarketresearch.com/reports/global-autoimmune-hemolytic-anemia-treatment-market?srsltid=AfmBOooqy9l817r2cusKBqvP9M_bItTac98KmbdV0sQ8veVcFCaSklEb",
          "https://www.linkedin.com/pulse/autoimmune-hemolytic-anemia-therapeutics-market-obunc/",
          "https://www.dennisgong.com/blog/newmedicines/"
        ],
        "pipeline_sources": [
          "https://pmc.ncbi.nlm.nih.gov/articles/PMC9313871/",
          "https://www.biopharmcatalyst.com/company/IONS/news/300234",
          "https://www.biopharmcatalyst.com/news/2025/biopharmcatalyst-weekly-watchlist-key-upcoming-catalysts-due-at-ash"
        ],
        "attributed_sources": [
          {
            "url": "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0323843",
            "title": "Prevalence and incidence of primary autoimmune hemolytic anemia ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://journals.lww.com/ajg/fulltext/2020/10001/s0714_prevalence_of_autoimmune_hemolytic_anemia_in.715.aspx",
            "title": "S0714 Prevalence of Autoimmune Hemolytic Anemia in...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/761164Orig1s000AdminCorres.pdf",
            "title": "761164Orig1s000 - accessdata.fda.gov",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022137Orig1s015lbl.pdf",
            "title": "fludarabine phosphate injection - accessdata.fda.gov",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://turkarchpediatr.org/Content/files/sayilar/30/TPA_53_2_129_130%5BA%5D.pdf",
            "title": "[PDF] Current treatment options for severe autoimmune hemolytic anemia",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9313871/",
            "title": "Fostamatinib for the treatment of warm antibody ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.biopharmcatalyst.com/company/IONS/news/300234",
            "title": "Ionis presents new data demonstrating long-term disease ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.databridgemarketresearch.com/reports/global-autoimmune-hemolytic-anemia-treatment-market?srsltid=AfmBOooqy9l817r2cusKBqvP9M_bItTac98KmbdV0sQ8veVcFCaSklEb",
            "title": "Global Autoimmune Hemolytic Anemia Treatment Market Size ...",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://www.linkedin.com/pulse/autoimmune-hemolytic-anemia-therapeutics-market-obunc/",
            "title": "Autoimmune Hemolytic Anemia Therapeutics Market Size 2026",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 8.0,
        "evidence_quality": 4.6,
        "market_opportunity": 8.3,
        "overall_priority": 7.2,
        "clinical_breakdown": {
          "response_rate_quality_weighted": 10.0,
          "safety_profile": 5.0,
          "organ_domain_breadth": 10.0,
          "safety_categories": [],
          "regulatory_flags": [],
          "efficacy_endpoint_count": 0,
          "efficacy_concordance": 1.0
        },
        "response_rate_score": 10.0,
        "safety_profile_score": 5.0,
        "endpoint_quality_score": null,
        "organ_domain_score": 10.0,
        "evidence_breakdown": {
          "sample_size": 1.0,
          "publication_venue": 10.0,
          "response_durability": 4.0,
          "extraction_completeness": 4.9
        },
        "sample_size_score": 1.0,
        "publication_venue_score": 10.0,
        "followup_duration_score": 4.0,
        "extraction_completeness_score": 4.9,
        "market_breakdown": {
          "competitors": 7.0,
          "market_size": 8.0,
          "unmet_need": 10.0
        },
        "competitors_score": 7.0,
        "market_size_score": 8.0,
        "unmet_need_score": 10.0
      },
      "rank": 4
    },
    {
      "extraction": {
        "source": {
          "pmid": "41136913",
          "doi": "10.1186/s12882-025-04487-4",
          "url": "https://pubmed.ncbi.nlm.nih.gov/41136913/",
          "title": "Iptacopan in C5 blockade refractory atypical hemolytic uremic syndrome with associated Castleman's disease: case report.",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Peer-reviewed journal",
          "is_open_access": false
        },
        "disease": "atypical hemolytic uremic syndrome (aHUS)",
        "disease_normalized": "Atypical Hemolytic Uremic Syndrome",
        "is_off_label": true,
        "is_relevant": true,
        "evidence_level": "Case Report",
        "patient_population": {
          "n_patients": 1,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "eculizumab",
            "ravulizumab"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "21-year-old Pakistani male with aHUS/CMTMA and complement factor H-related protein 4 rare genetic variant"
        },
        "treatment": {
          "drug_name": "iptacopan",
          "generic_name": "iptacopan",
          "mechanism": "Iptacopan binds to Factor B of the alternative complement pathway and regulates the cleavage of C3, generation of downstream effectors, and the amplification of the terminal pathway. In PNH, intravascular hemolysis (IVH) is mediated by the downstream membrane attack complex (MAC), while extravascular hemolysis (EVH) is facilitated by C3b opsonization. Iptacopan acts proximally in the alternative pathway of the complement cascade to control both C3b-mediated EVH and terminal complement-mediated IVH. In IgAN, the deposition of galactose deficient IgA1 (Gd-IgA1) containing immune complexes in the kidney locally activates the alternative complement pathway which is thought to contribute to the pathogenesis of IgAN. By binding to Factor B, iptacopan inhibits the alternative pathway. In C3G, overactivation of the alternative complement pathway leads to C3 cleavage within the glomeruli resulting in C3 deposition and inflammation, which are thought to contribute to the pathogenesis of C3G. By ",
          "target": null,
          "route_of_administration": "oral",
          "dose": "200 mg twice daily",
          "frequency": null,
          "duration": "10 months",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "1/1 (100%)",
          "responders_n": 1,
          "responders_pct": 100.0,
          "time_to_response": "within 2 weeks patient started making urine, dialysis discontinued within 2 months",
          "duration_of_response": "10 months before relapse due to concurrent Castleman's disease",
          "effect_size_description": "complete recovery - first time ever achieving normal serum creatinine and hemoglobin normalization",
          "primary_endpoint": "hematologic and renal recovery",
          "endpoint_result": "complete hematologic recovery with hemoglobin normalization to 13 g/dL, platelet recovery, renal function normalization to 0.8-1.0 mg/dL creatinine, and cessation of dialysis within 2 months",
          "durability_signal": null,
          "efficacy_summary": "Iptacopan achieved complete hematologic and renal recovery in a patient with aHUS refractory to C5 blockade. Patient achieved normal creatinine (0.8-1.0 mg/dL) and hemoglobin (13 g/dL) for the first time, with cessation of dialysis within 2 months."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": null,
          "sae_percentage": null,
          "discontinuations_n": 0,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "No adverse events were reported during the 10-month treatment period with iptacopan. The patient tolerated the medication well without any safety concerns mentioned.",
          "safety_profile": "Favorable"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Strong",
        "comparator_baseline": null,
        "follow_up_duration": "10 months on iptacopan, then additional follow-up with combination therapy",
        "key_findings": "First reported use of iptacopan for aHUS achieved complete recovery when C5 blockade failed. Subsequent relapse was due to concurrent Castleman's disease rather than treatment failure.",
        "detailed_efficacy_endpoints": [
          {
            "endpoint_name": "Serum creatinine",
            "endpoint_category": "Primary",
            "timepoint": "Baseline",
            "measurement_type": "Absolute value",
            "value": 5.4,
            "unit": "mg/dL",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 5.4,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Initial presentation value",
            "organ_domain": "Renal",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Serum creatinine",
            "endpoint_category": "Primary",
            "timepoint": "Response to eculizumab",
            "measurement_type": "Change from baseline",
            "value": 5.2,
            "unit": "mg/dL",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 7.3,
            "final_value": 5.2,
            "change_from_baseline": -2.1,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Partial response to eculizumab",
            "organ_domain": "Renal",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Serum creatinine",
            "endpoint_category": "Primary",
            "timepoint": "Response to ravulizumab",
            "measurement_type": "Change from baseline",
            "value": 1.2,
            "unit": "mg/dL",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 5.4,
            "final_value": 1.2,
            "change_from_baseline": -4.2,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Range 1-1.4 mg/dL, using midpoint",
            "organ_domain": "Renal",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Serum creatinine",
            "endpoint_category": "Primary",
            "timepoint": "Response to iptacopan",
            "measurement_type": "Change from baseline",
            "value": 0.9,
            "unit": "mg/dL",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 6.5,
            "final_value": 0.9,
            "change_from_baseline": -5.6,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Normalized to 0.8-1 mg/dL range, using midpoint",
            "organ_domain": "Renal",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Serum creatinine",
            "endpoint_category": "Primary",
            "timepoint": "Response to dual therapy",
            "measurement_type": "Absolute value",
            "value": 2.4,
            "unit": "mg/dL",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "final_value": 2.4,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "3-month follow-up after dual therapy",
            "organ_domain": "Renal",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Hemoglobin",
            "endpoint_category": "Primary",
            "timepoint": "Baseline",
            "measurement_type": "Absolute value",
            "value": 6.0,
            "unit": "g/dL",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 6.0,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Initial presentation value",
            "organ_domain": "Hematological",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Hemoglobin",
            "endpoint_category": "Primary",
            "timepoint": "Response to eculizumab",
            "measurement_type": "Change from baseline",
            "value": 7.5,
            "unit": "g/dL",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 6.0,
            "final_value": 7.5,
            "change_from_baseline": 1.5,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Remained between 7-8 g/dL, using midpoint",
            "organ_domain": "Hematological",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Hemoglobin",
            "endpoint_category": "Primary",
            "timepoint": "Response to ravulizumab",
            "measurement_type": "Change from baseline",
            "value": 9.0,
            "unit": "g/dL",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 6.0,
            "final_value": 9.0,
            "change_from_baseline": 3.0,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Improved to 8-10 g/dL range, using midpoint",
            "organ_domain": "Hematological",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Hemoglobin",
            "endpoint_category": "Primary",
            "timepoint": "Response to iptacopan",
            "measurement_type": "Change from baseline",
            "value": 13.0,
            "unit": "g/dL",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 6.5,
            "final_value": 13.0,
            "change_from_baseline": 6.5,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Normalized to 13 g/L",
            "organ_domain": "Hematological",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Hemoglobin",
            "endpoint_category": "Primary",
            "timepoint": "Response to dual therapy",
            "measurement_type": "Absolute value",
            "value": 11.5,
            "unit": "g/dL",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "final_value": 11.5,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "3-month follow-up after dual therapy",
            "organ_domain": "Hematological",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Platelets",
            "endpoint_category": "Primary",
            "timepoint": "Baseline",
            "measurement_type": "Absolute value",
            "value": 100.0,
            "unit": "thous/uL",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 100.0,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Range 84-116 thous/uL, using midpoint",
            "organ_domain": "Hematological",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Platelets",
            "endpoint_category": "Primary",
            "timepoint": "Response to ravulizumab",
            "measurement_type": "Change from baseline",
            "value": 125.0,
            "unit": "thous/uL",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 30.0,
            "final_value": 125.0,
            "change_from_baseline": 95.0,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Improved from 10-50 thous/uL to 100-150 thous/uL range",
            "organ_domain": "Hematological",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Platelets",
            "endpoint_category": "Primary",
            "timepoint": "Response to dual therapy",
            "measurement_type": "Absolute value",
            "value": 89.0,
            "unit": "thous/uL",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "final_value": 89.0,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "3-month follow-up after dual therapy",
            "organ_domain": "Hematological",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Dialysis independence",
            "endpoint_category": "Primary",
            "timepoint": "Response to ravulizumab",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "total_n": 1,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Off dialysis 3 months after switch to ravulizumab",
            "organ_domain": "Renal",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Dialysis independence",
            "endpoint_category": "Primary",
            "timepoint": "Response to iptacopan",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "total_n": 1,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Dialysis discontinued within 2 months of iptacopan",
            "organ_domain": "Renal",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Duration of dialysis independence",
            "endpoint_category": "Secondary",
            "timepoint": "Response to ravulizumab",
            "measurement_type": "Absolute value",
            "value": 19.0,
            "unit": "months",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "final_value": 19.0,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Remained dialysis-free for 19 months on ravulizumab",
            "organ_domain": "Renal",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Duration of dialysis independence",
            "endpoint_category": "Secondary",
            "timepoint": "Response to iptacopan",
            "measurement_type": "Absolute value",
            "value": 10.0,
            "unit": "months",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "final_value": 10.0,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "10 months after iptacopan initiation before relapse due to Castleman's disease",
            "organ_domain": "Renal",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "C3 level",
            "endpoint_category": "Secondary",
            "timepoint": "Baseline",
            "measurement_type": "Absolute value",
            "value": 117.0,
            "unit": "mg/dL",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 117.0,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Normal at initial presentation",
            "organ_domain": "Immunological",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "C3 level",
            "endpoint_category": "Secondary",
            "timepoint": "Relapse on ravulizumab",
            "measurement_type": "Change from baseline",
            "value": 197.0,
            "unit": "mg/dL",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 117.0,
            "final_value": 197.0,
            "change_from_baseline": 80.0,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Increased during relapse",
            "organ_domain": "Immunological",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "C5b-9 level",
            "endpoint_category": "Secondary",
            "timepoint": "Pre-iptacopan baseline",
            "measurement_type": "Absolute value",
            "value": 234.0,
            "unit": "ng/mL",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 234.0,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Baseline before iptacopan initiation",
            "organ_domain": "Immunological",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "C5b-9 level",
            "endpoint_category": "Secondary",
            "timepoint": "8 months on iptacopan",
            "measurement_type": "Change from baseline",
            "value": 250.0,
            "unit": "ng/mL",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 234.0,
            "final_value": 250.0,
            "change_from_baseline": 16.0,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Slight increase at 8 months",
            "organ_domain": "Immunological",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "C5b-9 level",
            "endpoint_category": "Secondary",
            "timepoint": "Relapse on iptacopan",
            "measurement_type": "Change from baseline",
            "value": 853.9,
            "unit": "ng/mL",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 234.0,
            "final_value": 853.9,
            "change_from_baseline": 619.9,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Marked elevation during relapse, reflecting lack of effective C5 blockade",
            "organ_domain": "Immunological",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "eGFR",
            "endpoint_category": "Primary",
            "timepoint": "Relapse on iptacopan",
            "measurement_type": "Absolute value",
            "value": 16.5,
            "unit": "mL/min/1.73 m\u00b2",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "final_value": 16.5,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Range 15-18 mL/min/1.73 m\u00b2, using midpoint",
            "organ_domain": "Renal",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          }
        ],
        "detailed_safety_endpoints": [],
        "extraction_timestamp": "2025-12-08T00:19:58.682432",
        "extraction_confidence": 0.6,
        "extraction_confidence_detail": null,
        "extraction_method": "multi_stage",
        "extraction_stages_completed": [
          "section_identification",
          "efficacy_extraction",
          "safety_extraction"
        ],
        "data_sections_identified": {
          "baseline_tables": [],
          "efficacy_tables": [],
          "safety_tables": [],
          "efficacy_figures": [
            "Figure 2: Lab trends initial presentation showing LDH, serum creatinine, and hemoglobin over time with renal replacement therapy periods",
            "Figure 3: Lab trends on C5 blockade showing improvement with ravulizumab treatment",
            "Figure 4: Lab trends relapse presentation and remission showing response to iptacopan treatment",
            "Figure 5: Lab trends with IL-6 and factor B inhibition showing response to combined siltuximab and iptacopan therapy"
          ],
          "results_sections": [
            "Case report part 1 - initial presentation",
            "Case report part 2 - relapse while on C5 blockade",
            "Case report part 3 - relapse while on Iptacopan due to Castleman's disease"
          ],
          "patient_count": 1,
          "study_type": "Case Report",
          "has_quantitative_outcomes": true,
          "notes": "Single patient case report with detailed laboratory trends shown in figures rather than tables. Patient had complex disease course with initial response to ravulizumab, then breakthrough requiring iptacopan, followed by diagnosis of concurrent Castleman's disease requiring combination therapy. Figure 1 shows renal biopsy findings rather than clinical outcomes."
        }
      },
      "market_intelligence": {
        "disease": "Atypical Hemolytic Uremic Syndrome",
        "epidemiology": {
          "us_prevalence_estimate": "2-9 cases per million",
          "us_incidence_estimate": "0.11-2 cases per million annually",
          "global_prevalence": null,
          "patient_population_size": 1843,
          "prevalence_source": "aHUS Registry and multiple European/US studies",
          "prevalence_source_url": "https://ahusregistry.com/",
          "trend": null,
          "source_quality": "Secondary",
          "data_year": null,
          "geographic_scope": "US",
          "confidence": "Medium",
          "notes": "Wide range reported in prevalence estimates; incidence data primarily from European studies; one source estimates approaching 3000 aHUS patients in USA; accounts for only 5% of all HUS cases"
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Soliris (eculizumab)",
              "drug_class": "C5 complement inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Atypical Hemolytic Uremic Syndrome",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "FDA approved September 23, 2011 for atypical HUS to inhibit complement-mediated thrombotic microangiopathy. Humanized monoclonal antibody against C5 that inhibits terminal complement activation."
            },
            {
              "drug_name": "Ultomiris (ravulizumab-cwvz)",
              "drug_class": "C5 complement inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Atypical Hemolytic Uremic Syndrome",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "FDA approved October 18, 2019 for atypical HUS to inhibit complement-mediated thrombotic microangiopathy. Approved for adult and pediatric patients one month of age and older."
            }
          ],
          "approved_drug_names": [
            "Soliris (eculizumab)",
            "Ultomiris (ravulizumab-cwvz)"
          ],
          "num_approved_drugs": 2,
          "num_pipeline_therapies": 0,
          "pipeline_therapies": [],
          "pipeline_details": null,
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "Complement inhibitors eculizumab and ravulizumab are first-line standard of care for atypical HUS. Plasma exchange is considered second-line therapy when complement inhibitors are unavailable.",
          "unmet_need": false,
          "unmet_need_description": null,
          "competitive_landscape": "Two FDA-approved C5 complement inhibitors dominate the atypical HUS treatment landscape as first-line therapies. Bkemv (eculizumab-aeeb) was recently approved as the first interchangeable biosimilar to Soliris, providing additional treatment options.",
          "soc_source": "Medscape Hemolytic-Uremic Syndrome Treatment & Management - https://emedicine.medscape.com/article/201181-treatment"
        },
        "market_size_estimate": "$369M",
        "market_size_usd": 368600000.0,
        "growth_rate": "3-5% CAGR (estimated)",
        "tam_usd": 261000000.0,
        "tam_estimate": "$261M",
        "tam_rationale": "Of ~1,843 US patients with aHUS, ~80% are diagnosed (1,474), ~90% receive treatment given life-threatening nature (1,327). With eculizumab and ravulizumab as established first-line therapies, a new drug would likely compete for 1L market share or target treatment failures. A new entrant could capture 15-20% market share (~250 patients). At typical complement inhibitor pricing of ~$500K-600K/yr (similar to eculizumab's ultra-rare orphan pricing), TAM = 250 \u00d7 $522K = $261M.",
        "tam_sources": [
          "https://www.futuremarketinsights.com/reports/atypical-hemolytic-uremic-syndrome-treatment-market",
          "https://www.researchandmarkets.com/reports/6076145/complement-inhibitors-market-report?srsltid=AfmBOopSyTCokpYqEe0eu_8g_HSU5gSNgsV4mzD1MC1SPTYNmRNWMRc8",
          "https://pmc.ncbi.nlm.nih.gov/articles/PMC6939334/"
        ],
        "pipeline_sources": [
          "https://clinicaltrials.gov/study/NCT01522183",
          "https://www.clinicaltrials.gov/study/NCT04889430",
          "https://pubmed.ncbi.nlm.nih.gov/39105067/"
        ],
        "attributed_sources": [
          {
            "url": "https://ahusregistry.com/",
            "title": "aHUS Registry - Home",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3832913/",
            "title": "Update on hemolytic uremic syndrome: Diagnostic and therapeutic ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://emedicine.medscape.com/article/201181-treatment",
            "title": "Hemolytic-Uremic Syndrome Treatment & Management",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.drugs.com/history/soliris.html",
            "title": "Soliris (eculizumab) FDA Approval History",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.ncbi.nlm.nih.gov/books/NBK556038/",
            "title": "Hemolytic Uremic Syndrome - StatPearls - NCBI Bookshelf - NIH",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://clinicaltrials.gov/study/NCT01522183",
            "title": "Atypical Hemolytic-Uremic Syndrome (aHUS) Registry",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.clinicaltrials.gov/study/NCT04889430",
            "title": "NCT04889430 | Efficacy and Safety of Iptacopan (LNP023 ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.futuremarketinsights.com/reports/atypical-hemolytic-uremic-syndrome-treatment-market",
            "title": "Atypical Hemolytic Uremic Syndrome (aHUS) Treatment ...",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://www.researchandmarkets.com/reports/6076145/complement-inhibitors-market-report?srsltid=AfmBOopSyTCokpYqEe0eu_8g_HSU5gSNgsV4mzD1MC1SPTYNmRNWMRc8",
            "title": "Complement Inhibitors Market Report 2025 - Research and Markets",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 8.1,
        "evidence_quality": 5.7,
        "market_opportunity": 7.0,
        "overall_priority": 7.2,
        "clinical_breakdown": {
          "response_rate_quality_weighted": 6.3,
          "safety_profile": 9.0,
          "organ_domain_breadth": 10.0,
          "safety_categories": [],
          "regulatory_flags": [],
          "efficacy_endpoint_count": 23,
          "efficacy_concordance": 0.9
        },
        "response_rate_score": 6.3,
        "safety_profile_score": 9.0,
        "endpoint_quality_score": null,
        "organ_domain_score": 10.0,
        "evidence_breakdown": {
          "sample_size": 1.0,
          "publication_venue": 10.0,
          "response_durability": 7.0,
          "extraction_completeness": 7.2
        },
        "sample_size_score": 1.0,
        "publication_venue_score": 10.0,
        "followup_duration_score": 7.0,
        "extraction_completeness_score": 7.2,
        "market_breakdown": {
          "competitors": 7.0,
          "market_size": 6.0,
          "unmet_need": 8.0
        },
        "competitors_score": 7.0,
        "market_size_score": 6.0,
        "unmet_need_score": 8.0
      },
      "rank": 5
    },
    {
      "extraction": {
        "source": {
          "pmid": "40881710",
          "doi": "10.3389/fimmu.2025.1583506",
          "url": "https://pubmed.ncbi.nlm.nih.gov/40881710/",
          "title": "Successful treatment of transplant-associated thrombotic microangiopathy with iptacopan: a non-adult case study.",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Peer-reviewed journal",
          "is_open_access": false
        },
        "disease": "Transplant-associated thrombotic microangiopathy (TA-TMA)",
        "disease_normalized": "Transplantation-associated Thrombotic Microangiopathy",
        "is_off_label": true,
        "is_relevant": true,
        "evidence_level": "Case Report",
        "patient_population": {
          "n_patients": 1,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "plasma exchange",
            "hemodialysis",
            "eculizumab"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "17-year-old male with high-risk TA-TMA following allogeneic stem cell transplantation for myelodysplastic syndrome, presenting with multi-organ dysfunction"
        },
        "treatment": {
          "drug_name": "iptacopan",
          "generic_name": "iptacopan",
          "mechanism": "Iptacopan binds to Factor B of the alternative complement pathway and regulates the cleavage of C3, generation of downstream effectors, and the amplification of the terminal pathway. In PNH, intravascular hemolysis (IVH) is mediated by the downstream membrane attack complex (MAC), while extravascular hemolysis (EVH) is facilitated by C3b opsonization. Iptacopan acts proximally in the alternative pathway of the complement cascade to control both C3b-mediated EVH and terminal complement-mediated IVH. In IgAN, the deposition of galactose deficient IgA1 (Gd-IgA1) containing immune complexes in the kidney locally activates the alternative complement pathway which is thought to contribute to the pathogenesis of IgAN. By binding to Factor B, iptacopan inhibits the alternative pathway. In C3G, overactivation of the alternative complement pathway leads to C3 cleavage within the glomeruli resulting in C3 deposition and inflammation, which are thought to contribute to the pathogenesis of C3G. By ",
          "target": null,
          "route_of_administration": "oral",
          "dose": "200 mg twice daily",
          "frequency": null,
          "duration": "10 weeks",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "1/1 (100%)",
          "responders_n": 1,
          "responders_pct": 100.0,
          "time_to_response": "Significant improvement within 1 month, continued improvement over 10 weeks",
          "duration_of_response": "Response maintained through 10 weeks of follow-up",
          "effect_size_description": "Dramatic improvement in all TA-TMA markers with normalization of organ function",
          "primary_endpoint": "Improvement in TA-TMA laboratory markers including ACR, C5b-9, LDH, platelet count, and haptoglobin",
          "endpoint_result": "ACR decreased from 342.3 to 29.78 mg/g, C5b-9 decreased from 739 to 163 ng/mL, LDH decreased from 615 to 279 U/L, platelets increased from 27 to 146 \u00d7 10^9/L, haptoglobin recovered from <0.06 to 0.38 g/L",
          "durability_signal": null,
          "efficacy_summary": "The patient showed significant improvements in all TA-TMA laboratory markers within 4 weeks of iptacopan treatment, with continued improvement over 10 weeks. Multi-organ dysfunction resolved with normalization of liver and kidney function, and the patient resumed normal daily activities."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": null,
          "sae_percentage": null,
          "discontinuations_n": 0,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "Iptacopan was well-tolerated with a favorable safety profile. No adverse events were reported during the 10-week treatment period.",
          "safety_profile": "Favorable"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Strong",
        "comparator_baseline": null,
        "follow_up_duration": "10 weeks",
        "key_findings": "Iptacopan successfully treated high-risk TA-TMA with dramatic improvement in all disease markers and resolution of multi-organ dysfunction. This represents a novel therapeutic approach targeting the proximal complement pathway.",
        "detailed_efficacy_endpoints": [
          {
            "endpoint_name": "LDH",
            "endpoint_category": "Exploratory",
            "timepoint": "Pre-iptacopan (baseline)",
            "measurement_type": "Absolute value",
            "value": 417.0,
            "unit": "U/L",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 417.0,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Median value, marker of hemolysis",
            "organ_domain": "Hematological",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "LDH",
            "endpoint_category": "Exploratory",
            "timepoint": "Week 10",
            "measurement_type": "Absolute value",
            "value": 250.0,
            "unit": "U/L",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 417.0,
            "final_value": 250.0,
            "change_from_baseline": -167.0,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Median value at week 10",
            "organ_domain": "Hematological",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "ACR",
            "endpoint_category": "Exploratory",
            "timepoint": "Pre-iptacopan (baseline)",
            "measurement_type": "Absolute value",
            "value": 42.4,
            "unit": "mg/g",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 42.4,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Urinary microalbumin/creatinine ratio, median value",
            "organ_domain": "Renal",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "ACR",
            "endpoint_category": "Exploratory",
            "timepoint": "Week 10",
            "measurement_type": "Absolute value",
            "value": 29.78,
            "unit": "mg/g",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 42.4,
            "final_value": 29.78,
            "change_from_baseline": -12.62,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Urinary microalbumin/creatinine ratio",
            "organ_domain": "Renal",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "C5b-9",
            "endpoint_category": "Exploratory",
            "timepoint": "Pre-iptacopan (baseline)",
            "measurement_type": "Absolute value",
            "value": 431.0,
            "unit": "ng/mL",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 431.0,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Complement activation marker",
            "organ_domain": "Immunological",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "C5b-9",
            "endpoint_category": "Exploratory",
            "timepoint": "Week 10",
            "measurement_type": "Absolute value",
            "value": 163.0,
            "unit": "ng/mL",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 431.0,
            "final_value": 163.0,
            "change_from_baseline": -268.0,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Complement activation marker",
            "organ_domain": "Immunological",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Haptoglobin",
            "endpoint_category": "Exploratory",
            "timepoint": "Pre-iptacopan (baseline)",
            "measurement_type": "Absolute value",
            "value": 0.06,
            "unit": "g/L",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 0.06,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Marker of hemolysis",
            "organ_domain": "Hematological",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "Haptoglobin",
            "endpoint_category": "Exploratory",
            "timepoint": "Week 10",
            "measurement_type": "Absolute value",
            "value": 0.38,
            "unit": "g/L",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 0.06,
            "final_value": 0.38,
            "change_from_baseline": 0.32,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Marker of hemolysis recovery",
            "organ_domain": "Hematological",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "PLT",
            "endpoint_category": "Exploratory",
            "timepoint": "Pre-iptacopan (baseline)",
            "measurement_type": "Absolute value",
            "value": 24.0,
            "unit": "10^9/L",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 24.0,
            "final_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Platelet count, median value",
            "organ_domain": "Hematological",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          },
          {
            "endpoint_name": "PLT",
            "endpoint_category": "Exploratory",
            "timepoint": "Week 10",
            "measurement_type": "Absolute value",
            "value": 146.0,
            "unit": "10^9/L",
            "total_n": 1,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 24.0,
            "final_value": 146.0,
            "change_from_baseline": 122.0,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Platelet count recovery",
            "organ_domain": "Hematological",
            "is_validated_instrument": false,
            "instrument_quality_tier": 3
          }
        ],
        "detailed_safety_endpoints": [
          {
            "event_name": "Epstein-Barr virus infection",
            "event_category": "AE",
            "severity_grade": null,
            "patients_affected_n": 1,
            "patients_affected_pct": null,
            "events_total": null,
            "relatedness": null,
            "outcome": "Resolved",
            "action_taken": "None",
            "notes": "EBV DNA detected on 26 August, treated with rituximab weekly for three doses, subsequently became undetectable",
            "category_soc": "Infections",
            "infection_type": "Viral",
            "malignancy_type": null,
            "cv_type": null,
            "thromboembolic_type": null,
            "is_class_effect": false
          },
          {
            "event_name": "Cytomegalovirus infection",
            "event_category": "AE",
            "severity_grade": null,
            "patients_affected_n": 1,
            "patients_affected_pct": null,
            "events_total": null,
            "relatedness": null,
            "outcome": "Resolved",
            "action_taken": "None",
            "notes": "CMV DNA detected on 29 August, treated with cidofovir twice, subsequently became negative",
            "category_soc": "Infections",
            "infection_type": "Viral",
            "malignancy_type": null,
            "cv_type": null,
            "thromboembolic_type": null,
            "is_class_effect": false
          },
          {
            "event_name": "Klebsiella pneumoniae infection",
            "event_category": "AE",
            "severity_grade": null,
            "patients_affected_n": 1,
            "patients_affected_pct": null,
            "events_total": null,
            "relatedness": null,
            "outcome": "Resolved",
            "action_taken": "None",
            "notes": "Identified in sputum culture, treated with ceftriaxone based on drug sensitivity results, infection brought under control",
            "category_soc": "Infections",
            "infection_type": "Bacterial",
            "malignancy_type": null,
            "cv_type": null,
            "thromboembolic_type": null,
            "is_class_effect": false
          },
          {
            "event_name": "Pulmonary infection",
            "event_category": "AE",
            "severity_grade": null,
            "patients_affected_n": 1,
            "patients_affected_pct": null,
            "events_total": null,
            "relatedness": null,
            "outcome": "Resolved",
            "action_taken": "None",
            "notes": "Mentioned as part of multi-organ dysfunction, follow-up chest CT showed resolution of lung infection",
            "category_soc": "Infections",
            "infection_type": "Bacterial",
            "malignancy_type": null,
            "cv_type": null,
            "thromboembolic_type": null,
            "is_class_effect": false
          }
        ],
        "extraction_timestamp": "2025-12-08T00:14:18.369268",
        "extraction_confidence": 0.6,
        "extraction_confidence_detail": null,
        "extraction_method": "multi_stage",
        "extraction_stages_completed": [
          "section_identification",
          "efficacy_extraction",
          "safety_extraction"
        ],
        "data_sections_identified": {
          "baseline_tables": [],
          "efficacy_tables": [
            "Table 1: Clinical laboratory values showing pre-iptacopan and post-iptacopan values at 2, 4, 6, 8, and 10 weeks including LDH, ACR, C5b-9, Haptoglobin, and PLT measurements"
          ],
          "safety_tables": [],
          "efficacy_figures": [
            "Figure 1: Temporal changes in ACR levels over 12 weeks showing decline from peak of 370 mg/g",
            "Figure 2: Temporal changes in C5b-9 levels over 12 weeks showing sharp decline from 750 to 200 ng/mL",
            "Figure 3: Temporal changes in LDH levels over 10 weeks showing decline to 250 U/L",
            "Figure 4: Temporal changes in PLT levels over 12 weeks showing recovery from low levels",
            "Figure 5: Temporal changes in HAPT levels over 11 weeks showing recovery pattern"
          ],
          "results_sections": [
            "Case presentation section describing patient outcomes",
            "Clinical laboratory improvements including ACR decrease to 29.78 mg/g, C5b-9 levels drop to 163 ng/mL, LDH decrease to 279 U/L, platelet count increase to 146 \u00d7 10^9/L, and haptoglobin recovery to 0.38 g/L after 10 weeks"
          ],
          "patient_count": 1,
          "study_type": "Case Report",
          "has_quantitative_outcomes": true,
          "notes": "Single case report of 17-year-old male with high-risk TA-TMA treated with iptacopan showing significant improvement in multiple laboratory markers over 10 weeks of treatment"
        }
      },
      "market_intelligence": {
        "disease": "Transplantation-associated Thrombotic Microangiopathy",
        "epidemiology": {
          "us_prevalence_estimate": null,
          "us_incidence_estimate": "12% of allogeneic transplant recipients",
          "global_prevalence": null,
          "patient_population_size": 2880,
          "prevalence_source": "Transplantation and Cellular Therapy",
          "prevalence_source_url": "https://www.astctjournal.org/article/S2666-6367(22)00029-X/fulltext",
          "trend": null,
          "source_quality": "Primary",
          "data_year": 2022,
          "geographic_scope": "Global",
          "confidence": "Medium",
          "notes": "Pooled incidence from meta-analysis shows 12% of allogeneic transplant recipients develop TA-TMA. US patient estimate based on approximately 24,000 annual allogeneic transplants in US. Incidence varies widely (3-39%) depending on diagnostic criteria used, with provider/clinician diagnosis reporting lowest rates at 3%"
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Eculizumab",
              "drug_class": "Complement C5 inhibitor",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "Used off-label as second-line treatment for TA-TMA based on complement pathway involvement, but not FDA-approved for transplantation-associated TMA specifically"
            },
            {
              "drug_name": "Ravulizumab",
              "drug_class": "Complement C5 inhibitor",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "Long-acting complement inhibitor used off-label for TA-TMA, but not FDA-approved for transplantation-associated TMA specifically"
            },
            {
              "drug_name": "Rituximab",
              "drug_class": "CD20 monoclonal antibody",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "Used off-label as second-line treatment for TA-TMA, but not FDA-approved for transplantation-associated TMA specifically"
            }
          ],
          "approved_drug_names": [],
          "num_approved_drugs": 0,
          "num_pipeline_therapies": 2,
          "pipeline_therapies": [
            {
              "drug_name": "ravulizumab (Ultomiris)",
              "company": "AstraZeneca",
              "mechanism": "C5 complement inhibitor",
              "phase": "Phase 3",
              "trial_id": "ALXN1210-TMA-314",
              "expected_completion": null
            },
            {
              "drug_name": "defibrotide",
              "company": null,
              "mechanism": null,
              "phase": "Phase 3",
              "trial_id": "NCT03384693",
              "expected_completion": null
            }
          ],
          "pipeline_details": "The transplantation-associated thrombotic microangiopathy pipeline includes ravulizumab in Phase 3 trials for pediatric patients and defibrotide in prophylaxis trials. Multiple therapeutic agents are being tested in ongoing clinical trials targeting this high mortality condition.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "First-line treatment focuses on identifying and removing triggering causes with supportive care including discontinuation of calcineurin inhibitors. Second-line treatments include plasma exchange, complement inhibitors like eculizumab, rituximab, and defibrotide used off-label.",
          "unmet_need": true,
          "unmet_need_description": "No FDA-approved treatments specifically for transplantation-associated thrombotic microangiopathy exist, with mortality rates of 50-90%. Current treatment relies on supportive care and off-label use of therapies approved for other conditions.",
          "competitive_landscape": "The field represents a significant unmet medical need with no FDA-approved branded innovative treatments for TA-TMA specifically. Nomacopan has orphan designation but is not yet FDA-approved, while current therapies like eculizumab are used off-label based on complement pathway involvement.",
          "soc_source": "Frontiers in Immunology and Nature Reviews"
        },
        "market_size_estimate": "$576M",
        "market_size_usd": 576000000.0,
        "growth_rate": "5-8% CAGR (high unmet need)",
        "tam_usd": 172800000.0,
        "tam_estimate": "$172.8M",
        "tam_rationale": "Of 2,880 global TA-TMA patients, ~80% are diagnosed (2,304), ~90% receive treatment given high severity (2,074). With no approved drugs and high mortality, a new targeted therapy could capture 40-50% market share (~900 patients). At $192K/yr pricing (similar to complement inhibitor eculizumab used off-label), TAM = $172.8M. Ultra-rare orphan indication with high unmet need supports premium pricing and strong penetration.",
        "tam_sources": [
          "https://www.openpr.com/news/4007899/thrombotic-microangiopathy-treatment-market-size-in-7mm",
          "https://www.nature.com/articles/s41409-021-01283-0",
          "https://www.astctjournal.org/article/S2666-6367(25)01226-6/fulltext"
        ],
        "pipeline_sources": [
          "https://www.astrazeneca.com/content/astraz/media-centre/medical-releases/ultomiris-ravulizumab-meaningful-survival-87-at-26-weeks-children-thrombotic-mp-after-haematopoietic-stem-cell-transplant-phase-iii-open-label-trial.html",
          "http://clinicaltrials.gov/show/NCT03384693",
          "https://www.astctjournal.org/article/S2666-6367(25)01226-6/fulltext"
        ],
        "attributed_sources": [
          {
            "url": "https://www.astctjournal.org/article/S2666-6367(22)00029-X/fulltext",
            "title": "Incidence and Risk Factors of Transplantation-Associated ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://pubmed.ncbi.nlm.nih.gov/35042011/",
            "title": "Incidence and Risk Factors of Transplantation-Associated ... - PubMed",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=698219",
            "title": "Search Orphan Drug Designations and Approvals - FDA",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://cme.medscape.com/viewarticle/999440_2",
            "title": "Optimizing Care for Patients With aHUS, HSCT-TMA, and ...",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1583506/full",
            "title": "Successful treatment of transplant-associated thrombotic ... - Frontiers",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://www.astrazeneca.com/content/astraz/media-centre/medical-releases/ultomiris-ravulizumab-meaningful-survival-87-at-26-weeks-children-thrombotic-mp-after-haematopoietic-stem-cell-transplant-phase-iii-open-label-trial.html",
            "title": "Ultomiris (ravulizumab) demonstrated clinically meaningful ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "http://clinicaltrials.gov/show/NCT03384693",
            "title": "NCT03384693 | Defibrotide TMA Prophylaxis Pilot Trial",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.openpr.com/news/4007899/thrombotic-microangiopathy-treatment-market-size-in-7mm",
            "title": "Thrombotic Microangiopathy Treatment Market Size in 7MM",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://www.nature.com/articles/s41409-021-01283-0",
            "title": "Transplant-associated thrombotic microangiopathy - Nature",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 7.2,
        "evidence_quality": 4.7,
        "market_opportunity": 9.0,
        "overall_priority": 7.0,
        "clinical_breakdown": {
          "response_rate_quality_weighted": 6.3,
          "safety_profile": 6.8,
          "organ_domain_breadth": 10.0,
          "safety_categories": [
            "serious_infection"
          ],
          "regulatory_flags": [
            "serious_infection"
          ],
          "efficacy_endpoint_count": 10,
          "efficacy_concordance": 0.9
        },
        "response_rate_score": 6.3,
        "safety_profile_score": 6.8,
        "endpoint_quality_score": null,
        "organ_domain_score": 10.0,
        "evidence_breakdown": {
          "sample_size": 1.0,
          "publication_venue": 10.0,
          "response_durability": 3.0,
          "extraction_completeness": 7.2
        },
        "sample_size_score": 1.0,
        "publication_venue_score": 10.0,
        "followup_duration_score": 3.0,
        "extraction_completeness_score": 7.2,
        "market_breakdown": {
          "competitors": 10.0,
          "market_size": 7.0,
          "unmet_need": 10.0
        },
        "competitors_score": 10.0,
        "market_size_score": 7.0,
        "unmet_need_score": 10.0
      },
      "rank": 6
    },
    {
      "extraction": {
        "source": {
          "pmid": null,
          "doi": null,
          "url": "https://pubmed.ncbi.nlm.nih.gov/41016978/",
          "title": "Treatment of transplantation-associated thrombotic microangiopathy ...",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Web source",
          "is_open_access": false
        },
        "disease": "Transplantation-associated thrombotic microangiopathy (TA-TMA)",
        "disease_normalized": "Transplantation-associated Thrombotic Microangiopathy",
        "is_off_label": true,
        "is_relevant": true,
        "evidence_level": "Case Series",
        "patient_population": {
          "n_patients": 2,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [],
          "disease_severity": null,
          "comorbidities": null,
          "description": "40-year-old male with early T-cell precursor acute lymphoblastic leukemia with early-onset TA-TMA post-HSCT; 41-year-old female with acute myeloid leukemia arising from myelodysplastic syndrome with delayed-onset TA-TMA after allo-HSCT"
        },
        "treatment": {
          "drug_name": "iptacopan",
          "generic_name": "iptacopan",
          "mechanism": "Iptacopan binds to Factor B of the alternative complement pathway and regulates the cleavage of C3, generation of downstream effectors, and the amplification of the terminal pathway. In PNH, intravascular hemolysis (IVH) is mediated by the downstream membrane attack complex (MAC), while extravascular hemolysis (EVH) is facilitated by C3b opsonization. Iptacopan acts proximally in the alternative pathway of the complement cascade to control both C3b-mediated EVH and terminal complement-mediated IVH. In IgAN, the deposition of galactose deficient IgA1 (Gd-IgA1) containing immune complexes in the kidney locally activates the alternative complement pathway which is thought to contribute to the pathogenesis of IgAN. By binding to Factor B, iptacopan inhibits the alternative pathway. In C3G, overactivation of the alternative complement pathway leads to C3 cleavage within the glomeruli resulting in C3 deposition and inflammation, which are thought to contribute to the pathogenesis of C3G. By ",
          "target": null,
          "route_of_administration": null,
          "dose": null,
          "frequency": null,
          "duration": null,
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "2/2 (100%)",
          "responders_n": 2,
          "responders_pct": 100.0,
          "time_to_response": null,
          "duration_of_response": null,
          "effect_size_description": "Significant clinical and biochemical recovery",
          "primary_endpoint": "Clinical and biochemical recovery",
          "endpoint_result": "Significant clinical and biochemical recovery in both patients",
          "durability_signal": null,
          "efficacy_summary": "Both patients achieved significant clinical and biochemical recovery following iptacopan treatment. The cases demonstrate successful management of TA-TMA with complement inhibition."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": null,
          "sae_percentage": null,
          "discontinuations_n": null,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "Safety data not reported in this abstract. No adverse events or safety concerns mentioned.",
          "safety_profile": "Unknown"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Moderate",
        "comparator_baseline": null,
        "follow_up_duration": null,
        "key_findings": "Iptacopan demonstrated efficacy in treating TA-TMA post-HSCT with successful clinical recovery in both cases.",
        "detailed_efficacy_endpoints": [],
        "detailed_safety_endpoints": [],
        "extraction_timestamp": "2025-12-08T00:20:10.270521",
        "extraction_confidence": 0.5,
        "extraction_confidence_detail": null,
        "extraction_method": "single_pass",
        "extraction_stages_completed": [],
        "data_sections_identified": null
      },
      "market_intelligence": {
        "disease": "Transplantation-associated Thrombotic Microangiopathy",
        "epidemiology": {
          "us_prevalence_estimate": null,
          "us_incidence_estimate": "12% of allogeneic transplant recipients",
          "global_prevalence": null,
          "patient_population_size": 2880,
          "prevalence_source": "Transplantation and Cellular Therapy",
          "prevalence_source_url": "https://www.astctjournal.org/article/S2666-6367(22)00029-X/fulltext",
          "trend": null,
          "source_quality": "Primary",
          "data_year": 2022,
          "geographic_scope": "Global",
          "confidence": "Medium",
          "notes": "Pooled incidence from meta-analysis shows 12% of allogeneic transplant recipients develop TA-TMA. US patient estimate based on approximately 24,000 annual allogeneic transplants in US. Incidence varies widely (3-39%) depending on diagnostic criteria used, with provider/clinician diagnosis reporting lowest rates at 3%"
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Eculizumab",
              "drug_class": "Complement C5 inhibitor",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "Used off-label as second-line treatment for TA-TMA based on complement pathway involvement, but not FDA-approved for transplantation-associated TMA specifically"
            },
            {
              "drug_name": "Ravulizumab",
              "drug_class": "Complement C5 inhibitor",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "Long-acting complement inhibitor used off-label for TA-TMA, but not FDA-approved for transplantation-associated TMA specifically"
            },
            {
              "drug_name": "Rituximab",
              "drug_class": "CD20 monoclonal antibody",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "Used off-label as second-line treatment for TA-TMA, but not FDA-approved for transplantation-associated TMA specifically"
            }
          ],
          "approved_drug_names": [],
          "num_approved_drugs": 0,
          "num_pipeline_therapies": 2,
          "pipeline_therapies": [
            {
              "drug_name": "ravulizumab (Ultomiris)",
              "company": "AstraZeneca",
              "mechanism": "C5 complement inhibitor",
              "phase": "Phase 3",
              "trial_id": "ALXN1210-TMA-314",
              "expected_completion": null
            },
            {
              "drug_name": "defibrotide",
              "company": null,
              "mechanism": null,
              "phase": "Phase 3",
              "trial_id": "NCT03384693",
              "expected_completion": null
            }
          ],
          "pipeline_details": "The transplantation-associated thrombotic microangiopathy pipeline includes ravulizumab in Phase 3 trials for pediatric patients and defibrotide in prophylaxis trials. Multiple therapeutic agents are being tested in ongoing clinical trials targeting this high mortality condition.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "First-line treatment focuses on identifying and removing triggering causes with supportive care including discontinuation of calcineurin inhibitors. Second-line treatments include plasma exchange, complement inhibitors like eculizumab, rituximab, and defibrotide used off-label.",
          "unmet_need": true,
          "unmet_need_description": "No FDA-approved treatments specifically for transplantation-associated thrombotic microangiopathy exist, with mortality rates of 50-90%. Current treatment relies on supportive care and off-label use of therapies approved for other conditions.",
          "competitive_landscape": "The field represents a significant unmet medical need with no FDA-approved branded innovative treatments for TA-TMA specifically. Nomacopan has orphan designation but is not yet FDA-approved, while current therapies like eculizumab are used off-label based on complement pathway involvement.",
          "soc_source": "Frontiers in Immunology and Nature Reviews"
        },
        "market_size_estimate": "$576M",
        "market_size_usd": 576000000.0,
        "growth_rate": "5-8% CAGR (high unmet need)",
        "tam_usd": 172800000.0,
        "tam_estimate": "$172.8M",
        "tam_rationale": "Of 2,880 global TA-TMA patients, ~80% are diagnosed (2,304), ~90% receive treatment given high severity (2,074). With no approved drugs and high mortality, a new targeted therapy could capture 40-50% market share (~900 patients). At $192K/yr pricing (similar to complement inhibitor eculizumab used off-label), TAM = $172.8M. Ultra-rare orphan indication with high unmet need supports premium pricing and strong penetration.",
        "tam_sources": [
          "https://www.openpr.com/news/4007899/thrombotic-microangiopathy-treatment-market-size-in-7mm",
          "https://www.nature.com/articles/s41409-021-01283-0",
          "https://www.astctjournal.org/article/S2666-6367(25)01226-6/fulltext"
        ],
        "pipeline_sources": [
          "https://www.astrazeneca.com/content/astraz/media-centre/medical-releases/ultomiris-ravulizumab-meaningful-survival-87-at-26-weeks-children-thrombotic-mp-after-haematopoietic-stem-cell-transplant-phase-iii-open-label-trial.html",
          "http://clinicaltrials.gov/show/NCT03384693",
          "https://www.astctjournal.org/article/S2666-6367(25)01226-6/fulltext"
        ],
        "attributed_sources": [
          {
            "url": "https://www.astctjournal.org/article/S2666-6367(22)00029-X/fulltext",
            "title": "Incidence and Risk Factors of Transplantation-Associated ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://pubmed.ncbi.nlm.nih.gov/35042011/",
            "title": "Incidence and Risk Factors of Transplantation-Associated ... - PubMed",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=698219",
            "title": "Search Orphan Drug Designations and Approvals - FDA",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://cme.medscape.com/viewarticle/999440_2",
            "title": "Optimizing Care for Patients With aHUS, HSCT-TMA, and ...",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1583506/full",
            "title": "Successful treatment of transplant-associated thrombotic ... - Frontiers",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://www.astrazeneca.com/content/astraz/media-centre/medical-releases/ultomiris-ravulizumab-meaningful-survival-87-at-26-weeks-children-thrombotic-mp-after-haematopoietic-stem-cell-transplant-phase-iii-open-label-trial.html",
            "title": "Ultomiris (ravulizumab) demonstrated clinically meaningful ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "http://clinicaltrials.gov/show/NCT03384693",
            "title": "NCT03384693 | Defibrotide TMA Prophylaxis Pilot Trial",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.openpr.com/news/4007899/thrombotic-microangiopathy-treatment-market-size-in-7mm",
            "title": "Thrombotic Microangiopathy Treatment Market Size in 7MM",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://www.nature.com/articles/s41409-021-01283-0",
            "title": "Transplant-associated thrombotic microangiopathy - Nature",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 7.6,
        "evidence_quality": 2.9,
        "market_opportunity": 9.0,
        "overall_priority": 6.8,
        "clinical_breakdown": {
          "response_rate_quality_weighted": 10.0,
          "safety_profile": 5.0,
          "organ_domain_breadth": 8.0,
          "safety_categories": [],
          "regulatory_flags": [],
          "efficacy_endpoint_count": 0,
          "efficacy_concordance": 1.0
        },
        "response_rate_score": 10.0,
        "safety_profile_score": 5.0,
        "endpoint_quality_score": null,
        "organ_domain_score": 8.0,
        "evidence_breakdown": {
          "sample_size": 2.0,
          "publication_venue": 2.0,
          "response_durability": 4.0,
          "extraction_completeness": 4.4
        },
        "sample_size_score": 2.0,
        "publication_venue_score": 2.0,
        "followup_duration_score": 4.0,
        "extraction_completeness_score": 4.4,
        "market_breakdown": {
          "competitors": 10.0,
          "market_size": 7.0,
          "unmet_need": 10.0
        },
        "competitors_score": 10.0,
        "market_size_score": 7.0,
        "unmet_need_score": 10.0
      },
      "rank": 7
    },
    {
      "extraction": {
        "source": {
          "pmid": "40996634",
          "doi": "10.1007/s40620-025-02425-z",
          "url": "https://pubmed.ncbi.nlm.nih.gov/40996634/",
          "title": "Iptacopan/LNP023 and rituximab as rescue therapy in a patient with\u00a0systemic lupus erythematosus-associated atypical haemolytic uraemic syndrome.",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Peer-reviewed journal",
          "is_open_access": false
        },
        "disease": "systemic lupus erythematosus-associated atypical haemolytic uraemic syndrome",
        "disease_normalized": "Atypical Hemolytic Uremic Syndrome",
        "is_off_label": true,
        "is_relevant": true,
        "evidence_level": "Case Report",
        "patient_population": {
          "n_patients": 1,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": null,
          "disease_severity": null,
          "comorbidities": null,
          "description": "patient with systemic lupus erythematosus-associated atypical haemolytic uraemic syndrome"
        },
        "treatment": {
          "drug_name": "iptacopan",
          "generic_name": "iptacopan",
          "mechanism": "Iptacopan binds to Factor B of the alternative complement pathway and regulates the cleavage of C3, generation of downstream effectors, and the amplification of the terminal pathway. In PNH, intravascular hemolysis (IVH) is mediated by the downstream membrane attack complex (MAC), while extravascular hemolysis (EVH) is facilitated by C3b opsonization. Iptacopan acts proximally in the alternative pathway of the complement cascade to control both C3b-mediated EVH and terminal complement-mediated IVH. In IgAN, the deposition of galactose deficient IgA1 (Gd-IgA1) containing immune complexes in the kidney locally activates the alternative complement pathway which is thought to contribute to the pathogenesis of IgAN. By binding to Factor B, iptacopan inhibits the alternative pathway. In C3G, overactivation of the alternative complement pathway leads to C3 cleavage within the glomeruli resulting in C3 deposition and inflammation, which are thought to contribute to the pathogenesis of C3G. By ",
          "target": null,
          "route_of_administration": null,
          "dose": null,
          "frequency": null,
          "duration": null,
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": null,
          "responders_n": null,
          "responders_pct": null,
          "time_to_response": null,
          "duration_of_response": null,
          "effect_size_description": null,
          "primary_endpoint": null,
          "endpoint_result": null,
          "durability_signal": null,
          "efficacy_summary": "No efficacy data available in the provided abstract or full text content."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": null,
          "sae_percentage": null,
          "discontinuations_n": null,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "No safety data reported in the available content.",
          "safety_profile": "Unknown"
        },
        "outcome_result": "Unknown",
        "efficacy_signal": "None",
        "comparator_baseline": null,
        "follow_up_duration": null,
        "key_findings": "Case report describes use of iptacopan and rituximab as rescue therapy in SLE-associated aHUS but no outcome data provided.",
        "detailed_efficacy_endpoints": [],
        "detailed_safety_endpoints": [],
        "extraction_timestamp": "2025-12-08T00:16:11.199950",
        "extraction_confidence": 0.5,
        "extraction_confidence_detail": null,
        "extraction_method": "single_pass",
        "extraction_stages_completed": [],
        "data_sections_identified": null
      },
      "market_intelligence": {
        "disease": "Atypical Hemolytic Uremic Syndrome",
        "epidemiology": {
          "us_prevalence_estimate": "2-9 cases per million",
          "us_incidence_estimate": "0.11-2 cases per million annually",
          "global_prevalence": null,
          "patient_population_size": 1843,
          "prevalence_source": "aHUS Registry and multiple European/US studies",
          "prevalence_source_url": "https://ahusregistry.com/",
          "trend": null,
          "source_quality": "Secondary",
          "data_year": null,
          "geographic_scope": "US",
          "confidence": "Medium",
          "notes": "Wide range reported in prevalence estimates; incidence data primarily from European studies; one source estimates approaching 3000 aHUS patients in USA; accounts for only 5% of all HUS cases"
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Soliris (eculizumab)",
              "drug_class": "C5 complement inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Atypical Hemolytic Uremic Syndrome",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "FDA approved September 23, 2011 for atypical HUS to inhibit complement-mediated thrombotic microangiopathy. Humanized monoclonal antibody against C5 that inhibits terminal complement activation."
            },
            {
              "drug_name": "Ultomiris (ravulizumab-cwvz)",
              "drug_class": "C5 complement inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Atypical Hemolytic Uremic Syndrome",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "FDA approved October 18, 2019 for atypical HUS to inhibit complement-mediated thrombotic microangiopathy. Approved for adult and pediatric patients one month of age and older."
            }
          ],
          "approved_drug_names": [
            "Soliris (eculizumab)",
            "Ultomiris (ravulizumab-cwvz)"
          ],
          "num_approved_drugs": 2,
          "num_pipeline_therapies": 0,
          "pipeline_therapies": [],
          "pipeline_details": null,
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "Complement inhibitors eculizumab and ravulizumab are first-line standard of care for atypical HUS. Plasma exchange is considered second-line therapy when complement inhibitors are unavailable.",
          "unmet_need": false,
          "unmet_need_description": null,
          "competitive_landscape": "Two FDA-approved C5 complement inhibitors dominate the atypical HUS treatment landscape as first-line therapies. Bkemv (eculizumab-aeeb) was recently approved as the first interchangeable biosimilar to Soliris, providing additional treatment options.",
          "soc_source": "Medscape Hemolytic-Uremic Syndrome Treatment & Management - https://emedicine.medscape.com/article/201181-treatment"
        },
        "market_size_estimate": "$369M",
        "market_size_usd": 368600000.0,
        "growth_rate": "3-5% CAGR (estimated)",
        "tam_usd": 261000000.0,
        "tam_estimate": "$261M",
        "tam_rationale": "Of ~1,843 US patients with aHUS, ~80% are diagnosed (1,474), ~90% receive treatment given life-threatening nature (1,327). With eculizumab and ravulizumab as established first-line therapies, a new drug would likely compete for 1L market share or target treatment failures. A new entrant could capture 15-20% market share (~250 patients). At typical complement inhibitor pricing of ~$500K-600K/yr (similar to eculizumab's ultra-rare orphan pricing), TAM = 250 \u00d7 $522K = $261M.",
        "tam_sources": [
          "https://www.futuremarketinsights.com/reports/atypical-hemolytic-uremic-syndrome-treatment-market",
          "https://www.researchandmarkets.com/reports/6076145/complement-inhibitors-market-report?srsltid=AfmBOopSyTCokpYqEe0eu_8g_HSU5gSNgsV4mzD1MC1SPTYNmRNWMRc8",
          "https://pmc.ncbi.nlm.nih.gov/articles/PMC6939334/"
        ],
        "pipeline_sources": [
          "https://clinicaltrials.gov/study/NCT01522183",
          "https://www.clinicaltrials.gov/study/NCT04889430",
          "https://pubmed.ncbi.nlm.nih.gov/39105067/"
        ],
        "attributed_sources": [
          {
            "url": "https://ahusregistry.com/",
            "title": "aHUS Registry - Home",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3832913/",
            "title": "Update on hemolytic uremic syndrome: Diagnostic and therapeutic ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://emedicine.medscape.com/article/201181-treatment",
            "title": "Hemolytic-Uremic Syndrome Treatment & Management",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.drugs.com/history/soliris.html",
            "title": "Soliris (eculizumab) FDA Approval History",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.ncbi.nlm.nih.gov/books/NBK556038/",
            "title": "Hemolytic Uremic Syndrome - StatPearls - NCBI Bookshelf - NIH",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://clinicaltrials.gov/study/NCT01522183",
            "title": "Atypical Hemolytic-Uremic Syndrome (aHUS) Registry",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.clinicaltrials.gov/study/NCT04889430",
            "title": "NCT04889430 | Efficacy and Safety of Iptacopan (LNP023 ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.futuremarketinsights.com/reports/atypical-hemolytic-uremic-syndrome-treatment-market",
            "title": "Atypical Hemolytic Uremic Syndrome (aHUS) Treatment ...",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://www.researchandmarkets.com/reports/6076145/complement-inhibitors-market-report?srsltid=AfmBOopSyTCokpYqEe0eu_8g_HSU5gSNgsV4mzD1MC1SPTYNmRNWMRc8",
            "title": "Complement Inhibitors Market Report 2025 - Research and Markets",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 3.4,
        "evidence_quality": 4.4,
        "market_opportunity": 6.0,
        "overall_priority": 4.3,
        "clinical_breakdown": {
          "response_rate_quality_weighted": 1.5,
          "safety_profile": 5.0,
          "organ_domain_breadth": 4.0,
          "safety_categories": [],
          "regulatory_flags": [],
          "efficacy_endpoint_count": 0,
          "efficacy_concordance": 1.0
        },
        "response_rate_score": 1.5,
        "safety_profile_score": 5.0,
        "endpoint_quality_score": null,
        "organ_domain_score": 4.0,
        "evidence_breakdown": {
          "sample_size": 1.0,
          "publication_venue": 10.0,
          "response_durability": 4.0,
          "extraction_completeness": 3.8
        },
        "sample_size_score": 1.0,
        "publication_venue_score": 10.0,
        "followup_duration_score": 4.0,
        "extraction_completeness_score": 3.8,
        "market_breakdown": {
          "competitors": 7.0,
          "market_size": 6.0,
          "unmet_need": 5.0
        },
        "competitors_score": 7.0,
        "market_size_score": 6.0,
        "unmet_need_score": 5.0
      },
      "rank": 8
    },
    {
      "extraction": {
        "source": {
          "pmid": null,
          "doi": null,
          "url": "https://journals.lww.com/jasn/fulltext/2024/10001/iptacopan_in_c5_blockade_for_refractory_atypical.2807.aspx",
          "title": "Iptacopan in C5 Blockade for Refractory Atypical Hemolytic Uremic ...",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Web source",
          "is_open_access": false
        },
        "disease": "atypical Hemolytic Uremic Syndrome (aHUS)",
        "disease_normalized": "Atypical Hemolytic Uremic Syndrome",
        "is_off_label": true,
        "is_relevant": true,
        "evidence_level": "Case Report",
        "patient_population": {
          "n_patients": 1,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "C5 blockade"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "Patient with refractory atypical hemolytic uremic syndrome on C5 blockade therapy"
        },
        "treatment": {
          "drug_name": "iptacopan",
          "generic_name": "iptacopan",
          "mechanism": "Iptacopan binds to Factor B of the alternative complement pathway and regulates the cleavage of C3, generation of downstream effectors, and the amplification of the terminal pathway. In PNH, intravascular hemolysis (IVH) is mediated by the downstream membrane attack complex (MAC), while extravascular hemolysis (EVH) is facilitated by C3b opsonization. Iptacopan acts proximally in the alternative pathway of the complement cascade to control both C3b-mediated EVH and terminal complement-mediated IVH. In IgAN, the deposition of galactose deficient IgA1 (Gd-IgA1) containing immune complexes in the kidney locally activates the alternative complement pathway which is thought to contribute to the pathogenesis of IgAN. By binding to Factor B, iptacopan inhibits the alternative pathway. In C3G, overactivation of the alternative complement pathway leads to C3 cleavage within the glomeruli resulting in C3 deposition and inflammation, which are thought to contribute to the pathogenesis of C3G. By ",
          "target": null,
          "route_of_administration": null,
          "dose": null,
          "frequency": null,
          "duration": null,
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": null,
          "responders_n": null,
          "responders_pct": null,
          "time_to_response": null,
          "duration_of_response": null,
          "effect_size_description": null,
          "primary_endpoint": null,
          "endpoint_result": null,
          "durability_signal": null,
          "efficacy_summary": "This represents the first known case of factor B inhibition with iptacopan in treatment of aHUS in the United States. Specific efficacy outcomes were not detailed in the available abstract."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": null,
          "sae_percentage": null,
          "discontinuations_n": null,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "Safety outcomes were not reported in the available abstract portion of this case report.",
          "safety_profile": "Unknown"
        },
        "outcome_result": "Mixed",
        "efficacy_signal": "Weak",
        "comparator_baseline": null,
        "follow_up_duration": null,
        "key_findings": "First reported case of iptacopan use in aHUS treatment, representing a novel off-label application of factor B inhibition in this complement-mediated disease.",
        "detailed_efficacy_endpoints": [],
        "detailed_safety_endpoints": [],
        "extraction_timestamp": "2025-12-08T00:20:19.378002",
        "extraction_confidence": 0.5,
        "extraction_confidence_detail": null,
        "extraction_method": "single_pass",
        "extraction_stages_completed": [],
        "data_sections_identified": null
      },
      "market_intelligence": {
        "disease": "Atypical Hemolytic Uremic Syndrome",
        "epidemiology": {
          "us_prevalence_estimate": "2-9 cases per million",
          "us_incidence_estimate": "0.11-2 cases per million annually",
          "global_prevalence": null,
          "patient_population_size": 1843,
          "prevalence_source": "aHUS Registry and multiple European/US studies",
          "prevalence_source_url": "https://ahusregistry.com/",
          "trend": null,
          "source_quality": "Secondary",
          "data_year": null,
          "geographic_scope": "US",
          "confidence": "Medium",
          "notes": "Wide range reported in prevalence estimates; incidence data primarily from European studies; one source estimates approaching 3000 aHUS patients in USA; accounts for only 5% of all HUS cases"
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Soliris (eculizumab)",
              "drug_class": "C5 complement inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Atypical Hemolytic Uremic Syndrome",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "FDA approved September 23, 2011 for atypical HUS to inhibit complement-mediated thrombotic microangiopathy. Humanized monoclonal antibody against C5 that inhibits terminal complement activation."
            },
            {
              "drug_name": "Ultomiris (ravulizumab-cwvz)",
              "drug_class": "C5 complement inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Atypical Hemolytic Uremic Syndrome",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "FDA approved October 18, 2019 for atypical HUS to inhibit complement-mediated thrombotic microangiopathy. Approved for adult and pediatric patients one month of age and older."
            }
          ],
          "approved_drug_names": [
            "Soliris (eculizumab)",
            "Ultomiris (ravulizumab-cwvz)"
          ],
          "num_approved_drugs": 2,
          "num_pipeline_therapies": 0,
          "pipeline_therapies": [],
          "pipeline_details": null,
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "Complement inhibitors eculizumab and ravulizumab are first-line standard of care for atypical HUS. Plasma exchange is considered second-line therapy when complement inhibitors are unavailable.",
          "unmet_need": false,
          "unmet_need_description": null,
          "competitive_landscape": "Two FDA-approved C5 complement inhibitors dominate the atypical HUS treatment landscape as first-line therapies. Bkemv (eculizumab-aeeb) was recently approved as the first interchangeable biosimilar to Soliris, providing additional treatment options.",
          "soc_source": "Medscape Hemolytic-Uremic Syndrome Treatment & Management - https://emedicine.medscape.com/article/201181-treatment"
        },
        "market_size_estimate": "$369M",
        "market_size_usd": 368600000.0,
        "growth_rate": "3-5% CAGR (estimated)",
        "tam_usd": 261000000.0,
        "tam_estimate": "$261M",
        "tam_rationale": "Of ~1,843 US patients with aHUS, ~80% are diagnosed (1,474), ~90% receive treatment given life-threatening nature (1,327). With eculizumab and ravulizumab as established first-line therapies, a new drug would likely compete for 1L market share or target treatment failures. A new entrant could capture 15-20% market share (~250 patients). At typical complement inhibitor pricing of ~$500K-600K/yr (similar to eculizumab's ultra-rare orphan pricing), TAM = 250 \u00d7 $522K = $261M.",
        "tam_sources": [
          "https://www.futuremarketinsights.com/reports/atypical-hemolytic-uremic-syndrome-treatment-market",
          "https://www.researchandmarkets.com/reports/6076145/complement-inhibitors-market-report?srsltid=AfmBOopSyTCokpYqEe0eu_8g_HSU5gSNgsV4mzD1MC1SPTYNmRNWMRc8",
          "https://pmc.ncbi.nlm.nih.gov/articles/PMC6939334/"
        ],
        "pipeline_sources": [
          "https://clinicaltrials.gov/study/NCT01522183",
          "https://www.clinicaltrials.gov/study/NCT04889430",
          "https://pubmed.ncbi.nlm.nih.gov/39105067/"
        ],
        "attributed_sources": [
          {
            "url": "https://ahusregistry.com/",
            "title": "aHUS Registry - Home",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3832913/",
            "title": "Update on hemolytic uremic syndrome: Diagnostic and therapeutic ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://emedicine.medscape.com/article/201181-treatment",
            "title": "Hemolytic-Uremic Syndrome Treatment & Management",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.drugs.com/history/soliris.html",
            "title": "Soliris (eculizumab) FDA Approval History",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.ncbi.nlm.nih.gov/books/NBK556038/",
            "title": "Hemolytic Uremic Syndrome - StatPearls - NCBI Bookshelf - NIH",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://clinicaltrials.gov/study/NCT01522183",
            "title": "Atypical Hemolytic-Uremic Syndrome (aHUS) Registry",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.clinicaltrials.gov/study/NCT04889430",
            "title": "NCT04889430 | Efficacy and Safety of Iptacopan (LNP023 ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.futuremarketinsights.com/reports/atypical-hemolytic-uremic-syndrome-treatment-market",
            "title": "Atypical Hemolytic Uremic Syndrome (aHUS) Treatment ...",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://www.researchandmarkets.com/reports/6076145/complement-inhibitors-market-report?srsltid=AfmBOopSyTCokpYqEe0eu_8g_HSU5gSNgsV4mzD1MC1SPTYNmRNWMRc8",
            "title": "Complement Inhibitors Market Report 2025 - Research and Markets",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 4.2,
        "evidence_quality": 2.3,
        "market_opportunity": 5.3,
        "overall_priority": 4.0,
        "clinical_breakdown": {
          "response_rate_quality_weighted": 3.5,
          "safety_profile": 5.0,
          "organ_domain_breadth": 4.0,
          "safety_categories": [],
          "regulatory_flags": [],
          "efficacy_endpoint_count": 0,
          "efficacy_concordance": 1.0
        },
        "response_rate_score": 3.5,
        "safety_profile_score": 5.0,
        "endpoint_quality_score": null,
        "organ_domain_score": 4.0,
        "evidence_breakdown": {
          "sample_size": 1.0,
          "publication_venue": 2.0,
          "response_durability": 4.0,
          "extraction_completeness": 3.2
        },
        "sample_size_score": 1.0,
        "publication_venue_score": 2.0,
        "followup_duration_score": 4.0,
        "extraction_completeness_score": 3.2,
        "market_breakdown": {
          "competitors": 7.0,
          "market_size": 6.0,
          "unmet_need": 3.0
        },
        "competitors_score": 7.0,
        "market_size_score": 6.0,
        "unmet_need_score": 3.0
      },
      "rank": 9
    }
  ],
  "analysis_date": "2025-12-08T00:42:24.429603",
  "search_queries_used": [],
  "papers_screened": 30,
  "papers_extracted": 9,
  "total_input_tokens": 325838,
  "total_output_tokens": 38879,
  "estimated_cost_usd": 1.5607
}